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ABSTRACT
EFFECTS OF STZ INDUCED HYPERGLYCEMIA AND 
HYPERLIPEMIA ON PPARy 
AND ABCA1 IN A HAMSTER MODEL OF ATHEROGENESIS
By
Craig J. LaMarca 
University of New Hampshire, September 2006
Diabetes mellitus accelerates atherogenesis, but the exact mechanisms 
involved are unknown. This study examined the effects of hyperglycemia on the 
inflammatory transcription factor peroxisome proliferator activated receptor gamma 
(PPARy), known to be involved in atherogenesis, and the ATP binding cassette A1 
(ABCA1) protein that is a downstream product of PPARy. ABCA1 is a membrane 
bound transporter that is involved in reverse cholesterol transport via high density 
lipoprotein cholesterol (HDL-C). Hamsters were divided into two groups; 
hyperlipemic animals fed a high fat/high cholesterol control diet (C) and 
hyperlipemic/hyperglycemic animals that received the high fat diet and were 
administered streptozotocin. Half of the hamsters (23) in each group were sacrificed 
at 8 weeks and the other half at 24 weeks. To determine the role of PPARy and 
ABCA1 in atherogenesis, aortas were harvested for ELISA, western blot and 
immunohistochemical analyses of PPARy and ABCA1. The 8 week hyperlipemic 
hamsters had lower total cholesterol levels than the 8 week treated hamsters and both 
groups at 24 weeks. At 8 and 24 weeks, the TG levels of the treated hamsters’ were
viii
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elevated over controls, 24 week control values were higher than 8 week controls, but 
24 week treated values were lower than at 8 weeks (p<.05). Hemoglobin A1C 
(HbAlC) levels were higher (p<.001) in both treatment groups as compared to the 
controls but there were no differences between time points. HDL-C levels were lower 
in the 24 week treatment hamsters compared to all other groups. Non-HDL 
cholesterol values were higher (p<.05) in treatment groups at both time points and 24 
week controls were higher than 8 week controls. TC/HDL ratios were higher (p<.05) 
in both treatment groups as compared to controls and were higher (p<.05) in both 
groups at 24 weeks as compared to 8 weeks. Advanced fatty streak lesions were 
observed in the 8 week treatment group and in both the control and treatment 
hamsters at 24 weeks. The most advanced lesions were observed in the 24 week 
treatment animals. Both 8 week control and treated aortas as well as 24 week controls 
had mild focal reactions for PPARy and ABCA1 based on IHC, and while the 24 
week treatment sections had multi-focal, intense immunoreactivity. Thus, based on 
the immunohistochemical and ELIAS analyses, the 24 week treated animals showed a 
greater expression of PPARy and ABCA1. Although activated PPARy was detected 
by ELISA in all groups, there were no statistical differences between groups. 
However, average 8 week treated values were higher than 8 week controls and 24 
week controls were higher than both 8 week control and treated aortas. Treated values 
at 24 weeks declined as compared to controls. Due to extremely low protein 
concentrations, comparisons could not be made on western blot data although PPARy 
was detectable. Hyperglycemia as compared to hyperlipemia produced a more 
atherogenic lipid profile, more advanced arterial lesions, and observed increases in
ix
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PPARy and ABCA1 expression. The added metabolic stress of hyperglycemia in 
addition to hyperlipemia appeared to induce the further expression of PPARy and 
ABCA1, although the potential beneficial effects of this were outweighed by the 
extremely adverse lipid profile.
x
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CHAPTER 1 
INTRODUCTION
According to the American Heart Association, cardiovascular disease (CVD) is 
the leading cause of morbidity and mortality in the Western World [1]. In the United 
States alone, over 71 million American adults are living with one or more types of CVD 
and over 13 million of them have coronary heart disease (CHD) i.e., a coronary artery 
narrowing leading to hypoxia, inadequate nutrient provision and decreased metabolite 
removal [1]. CHD is also the leading cause of death in patients with type 2 diabetes, and 
the relative risk for developing CHD in diabetic patients is increased 2-4 fold [2]. 
Preliminary mortality data show that CVD was the underlying cause of over 37% of all 
deaths (2,444,000) in the United States in 2003, and over 58% of all deaths in 2002 [1]. 
The threat that CVD poses is certainly not a new one; CVD has been the number one 
killer in the US every year since 1900 with the exception of 1918, claims the lives of 
2500 Americans each day, and is responsible for one death every 35 seconds [1].
It is now well known that atherosclerotic coronary artery disease is a major 
complication of diabetes mellitus, a disease that affects the lives of more than 14 million 
Americans [3], One might assume that confounding variables might play a role in the 
increased incidence of CVD in diabetic patients, as a number of pre-defined risk factors 
for CVD such as elevated blood pressure and abnormal lipid profiles are more common 
in diabetics as compared to the general population. However, no more than 25% of the 
excess atherosclerotic risk from diabetes can be attributed to these known risk factors [4]. 
But, there is statistical evidence that CVD accounts for up to 80% of the deaths in
1
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patients with type 2 diabetes mellitus. The connection has focused worldwide research on 
the connection between type 2 diabetes and the increased incidence of CVD in these 
individuals. Many mechanisms have been proposed as commonalties between these 
disease states, but none as prevalent or convincing as inflammation. Overall, 
hyperglycemia, the root cause of both type 1 and 2 diabetes mellitus, seems to exacerbate 
the mechanisms that contribute to the development of CVD. More specifically, platelet 
hyperaggregability and or increased platelet adhesiveness and coagulation abnormalities, 
in addition to hypertension, all contribute to the accelerated development of 
atherosclerosis seen in type 2 diabetics [5]. On the cellular level, the hyperglycemia, 
hyperinsulinemia, and proatherogenic dyslipidemia associated with diabetes all 
contribute to complex vascular interactions that induce the atherogenic process. The 
dyslipidemia often observed in diabetics is associated with elevated levels of small, dense 
low density lipoprotein (LDL-C) particles, low levels of high density lipoprotein (HDL- 
C) as well as elevated triglycerides (150 mg/dL or higher). Elevated levels of 
triglycerides (hypertriglyceridemia), which is associated with increased circulating levels 
of triglyceride-rich lipoproteins, has been implicated as a risk factor for atherosclerosis 
and progression of coronary artery disease [6]. Hypertriglyceridemia is one of the 
metabolic abnormalities commonly observed in insulin resistant individuals. Diabetics 
experience extensive metabolic abnormalities such as increased circulating levels of 
inflammatory markers including C-reactive protein (CRP), TNF-a, as well as increased 
expression of the pro-inflammatory adhesion molecules intercellular adhesion molecule 
(ICAM) and vascular cell adhesion molecule (VCAM). The extent of biochemical 
changes in diabetics is complex and not-yet fully understood. One widely studied aspect
2
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of the biochemical abnormalities associated with insulin resistance and diabetes is the 
irreversible formation of advanced glycation end products (AGEs) with arterial wall 
proteins, lipids and nucleic acids. Increased circulating levels of AGEs and subsequent 
activation of their receptors (RAGE) on endothelial cells increases oxidative stress and 
activates protein kinase C, which eventually alters normal cellular function. The 
activation of the AGE-RAGE cascade induces the expression of adhesive molecules such 
as VC AM resulting in localization of circulating inflammatory cells to disease prone 
segments of the vasculature. This type of low-grade inflammation is a hallmark of 
diabetes which includes increasing circulating levels of inflammatory markers including 
CRP, fibrinogen, pro-inflammatory cytokines (TNF- a), adhesion molecules (ICAM and 
VCAM), IL-6 and a host of other inflammatory markers [7], Hence, the association of 
inflammation with both the development of type 2 diabetes and atherosclerosis suggests a 
possible connection where by diabetes mellitus may accelerate the progression of 
atherosclerosis. This study will examine the effects of hyperglycemia on mediators of 
inflammation and dyslipidemia elucidating possible connections between the two disease 
states.
Diabetes Mellitus
About 21 million people, or 7 percent of the United States population, are 
currently living with some form of diabetes mellitus, and another 6 million people are 
estimated to be living unknowingly with the disease [8]. Type I diabetes mellitus, also 
referred to as insulin dependent diabetes, affects approximately 10% of all diagnosed 
cases, and is characterized by immunologic destruction of the insulin producing (3-cells in
3
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the pancreas [9]. Type I diabetes most often occurs early in life (aka: juvenile diabetes) 
and is characterized by two distinct, general pathologies; an immune mediated and an 
idiopathic form. The immune diagnosis is a result of an autoimmune attack on the 
pancreatic beta cells rendering them unable to carry out their normal physiological 
function of insulin production. The second pathology, idiopathic, implies that the reason 
for beta cell destruction in unknown, and is not associated with the production of 
antibodies [9].
Type II diabetes accounts for the other 90% of the diagnosed cases and is a 
dynamic disease characterized by a resistance to the affects of insulin leading to a 
hyperglycemic state [9]. Unfortunately, according to national diabetes statistics, the 
average onset of type II diabetes precedes clinical diagnosis by several years [10]. To the 
patient, this means that the detrimental affects of the hyperglycemic state will take place 
prior to diagnosis and treatment. Over the past thirty years, a rising incidence in cases of 
type II diabetes can be attributed to an increase in prevalence of obesity and a general 
decline in physical activity [9]. Type 2 diabetes is characterized by an altered lipid profile 
and an overall pro-inflammatory state. Both excess fat and diminished physical activity 
are predisposing factors to type II diabetes, or more specifically insulin resistance. Insulin 
resistance (IR) is defined as the inability of peripheral tissue to take up endogenous 
glucose in response to normal, circulating levels of insulin. The primary cause of the 
common form of type 2 diabetes is not completely understood, but autoimmune 
mechanisms are not involved [11]. Cellular resistance to the effects of insulin is a factor 
in 60-80% of individuals with type 2 diabetes. Decreased beta cell responsiveness to 
plasma glucose levels is observed, along with abnormal glucagon secretion and beta cell
4
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dysfunction and eventual beta cell “burnout”. The islet dysfunction may be caused by a 
decrease in beta cell mass, abnormal function of the beta cells, alterations in the insulin 
receptor, or post-receptor events. Pancreatic changes among type II diabetic patients tend 
to be non-specific and in about 30% of these patients the changes are associated with 
increased amyloid deposition which can also lead to islet cell destruction. On top of 
detrimental pancreatic changes, liver changes related to elevated serum lipid levels are 
also observed in type 2 diabetics. Pancreatic and hepatic atrophy, although observed in 
diabetics and non-diabetics, occurs amongst diabetics with much greater frequency, and 
this increase in fatty infiltrates may also play a role in the development of amyloid 
deposits in the islets. Eventual pancreatic fibrosis also plays a role in loss of beta cell 
function in about 50% of individuals with type 2 diabetes [11], This decreased beta cell 
function leads to the advanced stages of type II diabetes characterized by decreased or 
diminished insulin secretion, insulin resistance (IR) and hyperglycemia.
Dyslipidemia and the Metabolic Syndrome
The observation that IR, as well as a number of other risk factors, such as obesity, 
hypertension and hypercholesterolemia are common in those who are predisposed to the 
development of cardiovascular disease lead to the suggestion of a metabolic syndrome, or 
a group of symptoms that collectively indicate an increased risk to CVD. Much debate 
and controversy has arisen over the idea of classifying a clustering of risk factors for 
cardiovascular disease. It is still vague how the syndrome should be represented and how 
the underlying mechanisms of the syndrome affect the predisposition to cardiovascular 
disease[12]. Generally, the metabolic syndrome clusters hypertension, dyslipidemia,
5
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impaired glucose tolerance and obesity, which are all well established risk factors for 
CVD. This clustered phenotype has been discussed since the 1980s as the “metabolic 
syndrome”, but prior to that, as early as the 1930s, it was described as syndrome X, the 
insulin resistance syndrome, and the deadly quartet [13]. More recently, due to the 
concept of metabolic abnormality or dysfunction within the syndrome, some authors have 
suggested the use of the dysmetabolic syndrome. There have been numerous attempts to 
standardize the definition of the metabolic syndrome, but no final definition has been 
established. One of the most widely used definitions, developed by the World Health 
Organization (WHO) in 1998 and revised in 1999, establishes that the human metabolic 
syndrome requires at least one of the following: type II diabetes mellitus or impaired 
glucose tolerance or glucose resistance. It also requires at least two of the following: 
hypertension (BP > 140/90 mm Hg), obesity (body mass index [BMI] > 30 kg/m2, or 
waist to hip ratio > 0.90 for male subjects or > 0.85 for female subjects), dyslipidemia 
(low HDL-C cholesterol [<.90mmol/L] and/or hypertriglyceridemia (> 1.7 mmol/L), or 
microalbuminuria (urinary albumin excretion rate > 20ug/min) [14]. The estimates of 
current prevalence among various populations are alarming and projections are for future 
increases. According to the National Health And Nutrition Examination Survey III 
(NHANES III), from 1988 to 1994,24% of adult Americans older than 20 years had the 
syndrome [15]. A recent study by Isomaa et al. reported that there is a 3-fold excess of 
CHD and stroke in subjects with the metabolic syndrome phenotype [16]. It has been 
estimated that 75% of people with type II diabetes meet the criteria for the metabolic 
syndrome, and many believe that obesity is a key etiologic factor in the development of 
the underlying insulin resistance [17]. Much effort and time has been spent toward the
6
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therapeutic treatment of the individual components of the metabolic syndrome, and many 
successful treatments have been developed. Physicians and pharmaceutical companies 
have targeted high blood pressure for the treatment of CVD for many years and have 
been relatively successful at producing drugs efficient at lowering hypertension. With the 
introduction of statins and advice on total lifestyle changes (TLC), the medical world has 
been able to target and decrease elevated LDL-C levels, but unfortunately these changes 
have not lead to concomitant decreases in incidence of CVD. The reasons for this discord 
are primarily unknown and have caused researchers to focus their studies on other risk 
factors. More recently, effort has been put toward treating the other abnormalities 
associated with dyslipidemia and insulin resistance; more specifically, a lower 
concentration of serum HDL-C cholesterol that is observed in this state.
The HDL-C Hypothesis
Epidemiological studies have identified elevated LDL-C as an independent risk 
factor for cardiovascular disease. Over the past ten years, clinical trials aimed at lowering 
LDL-C to decrease CVD risk have plainly established that reductions in LDL-C are 
associated with 30% to 40% reductions in clinical events [18]. Unfortunately, despite the 
efficacy of statins and other drugs in lowering serum LDL-C levels, many patients 
continue to experience detrimental cardiovascular events. Because the efficacy of 
targeting LDL-C to decrease CVD risk is still questionable, research has also been 
directed toward pharmacological, genetic, and dietary manipulations to raise serum HDL- 
C. Non-epidemiological studies have shown evidence that raising HDL-C could reduce 
the risk of CVD. One study, using transgenic animals that overexpress apolipoprtoein A1
7
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(apoAl), showed that increasing plasma HDL-C protected against diet induced and 
genetically determined atherosclerosis [19]. In another study, infusion of HDL-C in the 
form of apoA-l/phopholipids complexes was associated with regression of 
atherosclerosis in cholesterol fed rabbits [20]. This is important because by increasing 
HDL-C, not only can physicians target the initiation and progression of the disease, but 
they might actually be able to regress the progression of atherosclerotic lesions. In 
another study, 5 weekly infusions of apoA-1 Milano/phospholipid complexes in healthy 
men were shown to decrease total atheroma volume by 4.2% after an acute coronary 
event using intravascular ultrasound to quantitate coronary atheroma. These results all 
point at the fact that raising plasma levels of HDL-C could significantly decrease the 
onset and outcome of severe cardiovascular events. More clinical trials need to be carried 
out to measure surrogate endpoints of atherosclerosis, especially considering some of the 
disappointing results of the LDL-C trials after some promising initial results. If some of 
the rate limiting enzymes or integral proteins involved in HDL-C synthesis and 
processing could be up-regulated, hypothetically some of the associated risks of low 
serum HDL-C could be diminished.
The next step towards development of therapeutic options based on increasing 
HDL-C levels is understating the atheroprotective nature of the HDL-C molecule itself. 
Although our knowledge of it actions are not complete, there is evidence to support at 
least three atheroprotective mechanisms. HDL-C mediates the efflux o f cholesterol from 
peripheral cells (eg: arterial macrophages) in order for cholesterol to be returned to the 
liver for processing (breakdown and bile acid conversion). Cholesterol efflux from 
macrophages within the atheroma to the HDL-C molecule can occur by passive diffusion
8
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[21], by combining with the scavenger receptor B1 (SR-B1) [22] or by binding to the 
ATP Binding Cassette Transporter A1 (ABCA1) [23-25]. Nascent apoA is the preferred 
acceptor for the ABCA1 transporter mediated cholesterol efflux which after esterification 
of free cholesterol to cholesteryl esters (CE) by lecithin cholesterol acyltransferase 
(LCAT) is then converted to spherical a-HDL-C [26] (see figure 1). HDL-C is a pivotal 
component of the atheroprotective reverse cholesterol transport pathway, functioning as 
the shuttle of excess peripheral cholesterol to the liver for disposal as bile acids and 
cholesterol. A second major mechanism by which HDL-C may be protective against the 
progression of atherosclerosis is by protection of LDL-C from oxidation. Oxidatively 
modified LDL-C, unlike normal LDL-C, is recognized by scavenger receptors CD36 and 
SRA on macrophages resulting in the macrophage accumulation of CE and incidental 
foam cell formation. Oxidized lipids are transferred from LDL-C to HDL-C and are 
hydrolyzed by HDL-C paraoxonase and PAF acetylhydrolase [27]. A third mechanism by 
which HDL-C may protect against the onset of CVD is the selective decrease of 
endothelial cell adhesion molecules, which facilitate the binding of monocytes to the 
vessel wall subsequently promoting lesion development [28]. In order to elucidate the 
specifics of these mechanisms, it is important to know some of the basics of 
atherogenesis, and the role of reverse cholesterol transport.
Pathogenesis of Atherosclerosis
The normal arterial wall consists of three well-defined concentric layers; the 
innermost layer is the tunica intima, the middle layer is the tunica media, and the 
outermost layer is known as the tunica adventitia. These three layers are separated by
9
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concentric layers of elastin known as the external and internal elastic lamina. [3] The 
luminal surface of arteries is lined by a single contiguous layer of endothelial cells that 
rests upon a basement membrane superficial to the tunica intima. At one time, 
atherosclerosis was thought of as a passive process of lipid accumulation and plaque 
formation causing the endothelial cells to reflexively protrude into the luminal space. It is 
now known that atherosclerosis is a multi-factorial, dynamic process in which the 
endothelial cells regulate a wide variety of functions in the arterial wall including 
thrombosis, vascular tone, and leukocyte trafficking. Throughout the years, 
atherosclerosis has been characterized in many ways including: a degenerative disease 
process, a proliferative process and an accumulative process. One of the most widely 
accepted views is the “response to injury” hypothesis which was modified and tested by 
Russel Ross. This hypothesis implies that the lesions represent a specialized form of a 
“protective, inflammatory-fibroprliferative response to various forms of insult to the 
arterial wall.” Depending on the extent and duration of the insult, the defensive response 
may become chronic and excessive leading to a disease process [29].
In human atherosclerosis is characterized by three lesion stages: fatty streak, 
fibro-fatty and advanced. Fatty-streak lesions are characterized by nodular areas of lipid 
deposition; these early lesions, characterized by the development of macrophage ‘foam 
cells’ typically start by the age of 10, and increase to involve as much a 1/3 of the aortic 
surface in the third decade of life [3]. The production of these lipid-loaded macrophages 
which contain large amounts o f CE is a hallmark of both early and late atherosclerotic 
lesions. The accumulation of cholesterol in these cells is thought to be mediated primarily 
by the uptake of modified forms of LDL-C via scavenger receptors (e.g.,CD36 and SRA)
10
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[30]. Although there may be multiple proteins that aid in the cholesterol uptake, 
scavenger receptors A (SRA) and CD36 have been shown to play significant, quantitative 
roles. Research with Apo E-deficient mice lacking the SRA and CD36 receptors has 
demonstrated that these animals develop significantly less atherosclerosis than control 
Apo E knockout mice [31]. Cholesterol taken up by the macrophage via scavenger 
receptors in the oxLDL-C form consists o f free cholesterol as well as lysosome 
hydrolyzed cholesterol esters. Free cholesterol has a number of metabolic fates, including 
esterification by acyl coA: cholesterol acyltransferase (ACAT) as well as storage within 
the lipid droplets that characterize foam cells. Cholesterol deposits within these lipid 
droplets can in turn be hydrolyzed by cholesterol ester hydrolase, generating free 
cholesterol for incorporation into membranes as well as for transport out of the cell. The 
fate of cholesterol, once hydrolyzed, will be discussed in detail later, but involves two 
main processes: enzymatic modification to more soluble forms and efflux via membrane 
transporters.
As fatty streak lesions progress, there is a transition from the relatively simple 
fatty-streak to a more complex lesion, which is characterized by the transmigration of 
smooth muscle cells (SMCs) from the medial layer through the internal elastic lamina 
and into the intimal, or subendothelial space. These smooth muscle cells, now located in 
the intimal space have the ability to proliferate and take up modified lipoproteins, further 
contributing to foam cell formation. These SMCs also begin to produce and secrete extra­
cellular matrix proteins that strengthen and enlarge the plaque and form the beginnings of 
the fibrous cap [32, 33]. The lesion has now entered a phase of development that is 
influenced by interactions between monocytes/macrohages and T cells that result in a
11
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wide range of humoral and cellular responses. The lesion is in a self-perpetuating chronic 
inflammatory state: lesional T cells appear to be activated expressing both Thl and Th2 
cytokines [34], Pro-inflammatory cytokines produced within the atheroma provide a 
chemotactic stimulus to migrating leukocytes directing their adherence and migration into 
the intimal space. Once these blood-derived inflammatory cells are resident in the arterial 
wall, they sustain the local inflammatory response. As progression continues, T-cells are 
further stimulated, encountering protein antigens such as oxLDL-C, heat shock protein 60 
(HSP60), microbial antigens and simulataneous ligation of costimulatory receptors. The 
antigenic stimulation causes them to elaborate the production of pro-inflammatory 
cytokines such a y-interferon and TNFa. These cytokines can in turn stimulate 
macrophages proliferatively and phenotypically as well as vascular endothelial cells and 
SMCs. As this inflammatory process is perpetuated, the activated leukocytes and 
endogenous arterial cells can release fibrogenic mediators including a variety of growth 
factors that can promote proliferation of SMCs. As the SMCs proliferate and 
concentration of fibrogenic mediators increases, so does the extent of elaboration of the 
extracellular matrices becoming more characteristic of the advanced lesion.
Advanced lesions are characterized by a necrotic core, with increased calcified 
fibrous areas of the artery with visible ulceration. Inflammatory processes not only 
promote induction and evolution of the atherosclerotic plaque, but also contribute 
definitively to the acute thrombotic complications of atheroma [35]. Although the 
advanced lesion can lead to ischemic disease as a result of progressive narrowing of the 
arterial lumen, acute cardiovascular events that result in myocardial infarction and stroke 
(the major sequella of lesion formation) are believed to result from plaque rupture that
12
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leads to thrombosis[36]. If the plaque is unstable and raptures, plaque material including 
lipids and tissue factor (TF) are exposed to blood, initiating the coagulation cascade, 
platelet adherence and thrombosis. The highly concentrated, activated macrophages 
within the arterial lesion can produce proteolytic enzymes (e.g., matrix 
metalloproteinases (MMPs)) that are capable of degrading the collagen and extracellular 
matrix that aids in strengthening the plaque’s protective fibrous cap, rendering that cap 
thin, weak and susceptible to rapture, y -interferon, also produced by activated 
macrophages, can stop production of collagen by SMCs, limiting their capacity to further 
produce strengthening extracellular matrix proteins. As the lesions further progress 
toward the most advanced state, apoptosis and necrosis of lipid-laden macophages 
becomes morphologically evident. The cell death going on within the arterial lesion can 
result from cell to cell interactions and the highly concentrated cytokine environment; it 
can involve the actions of pro- and antiapoptotic proteins that include death receptors, 
proto-oncogenes, and tumor suppressor genes [37]. The release of insoluble and oxidized 
lipids from necrotic cells leads to the formation of the extracellular lipid “gruel” seen in 
advanced lesions.
Reverse Cholesterol Transport
Almost all animal cells synthesize cholesterol and import cholesterol from plasma 
lipoproteins in order to maintain normal function. At any time, there is a dynamic 
between the amount of free cholesterol and CEs within the cell, which is regulated by 
lipid metabolic enzymes: acyl-coenzyme A: cholesterol acyltransferase-1 (ACAT1) and 
neutral cholesterol ester hydrolases (nCEH) also known as hormone sensitive lipase
13
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(HSL). To maintain cholesterol balance and prevent cholesterol overload, cells must 
have the ability to export excess cholesterol. The only available reservoir for exported 
cholesterol deposition is the liver, owing its unique ability to synthesize bile acids and to 
transport cholesterol into bile. The process by which extrahepatic tissue controls the 
balance of cholesterol through its return to the liver is termed “reverse cholesterol 
transport (RCT).” In order to further study some of the key mediators involved in this 
protective mechanism in more detail, it is important to be able to understand the sequence 
of events in the reverse cholesterol transport process. Extrahepatic tissues, such as arterial 
tissue, synthesize cholesterol and also derive cholesterol through the uptake of 
lipoproteins via the LDL-C receptor and scavenger receptors. The cholesteryl esters in 
peripheral tissue are in a constant equilibrium with free cholesterol, through the opposing 
actions of ACAT and neutral cholesterol esterase. Free cholesterol (FC) is extruded to 
extracellular acceptors, most notably phospholipid/apoA-I disks (pre-J3-HDL-C). This 
process is directly dependent on functional ABCA1, a membrane bound cholesterol 
shuttle. Proper cholesterol loading is essential for the stability of HDL-C, the primary 
lipoprotein involved in reverse cholesterol transport. In the absence of sufficient 
cholesterol efflux, apoA-I is rapidly cleared from the circulation by the kidneys [38]. 
Cholesterol that associates with apoA-I/phospholipid disks is a substrate for LCAT, 
which transfers a fatty acyl chain from phosphatidylcholine to cholesterol, forming CE. 
The CE partitions into the hydrophobic core of the lipoprotein, thus forming spherical 
HDL-C particles. These particles can than deliver CE to the liver as well as to 
steroidogenic tissues. The interaction of spherical HDL-C particles with the scavenger 
receptor SR-BI leads to selective delivery of CEs, as the SRB1 receptor can only interact
14
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with spherical HDL-C particles. The CEs are hydrolyzed by a neutral cholesterol 
esterase, providing free cholesterol for secretion across the apical (bile canalicular) 
membrane of the hepatocyte and for bile acid synthesis. (See Figure 1)
M a t u r e  HDL-C 
A-I
M acrophage
N a s c e n t  HDL-C 
A-I
LCAT
i d a t i o n
Steroidegenic
Tissue VLDL-C/LDL-C
Figure 1: Reverse Cholesterol Transport Derivedfrom LipidsOnline.com
CE=Cholesteryl Ester, HDL-C=High Density Lipoprotein-Cholesterol, VLDL-Very Low 
Density Lipoprotein, LDL-C=Low Density Lipoprotein, LDL-R= Low Density 
Lipoprotein Receptor, FC=Free Cholesterol, SRBI=Scavenger Receptor B l,
SRA =Scavenger Receptor A 1, ABC A 1 =A TP Binding Cassette A l, LCA T=Lecithin 
cholesterol acyltransferase, CETP=Cholesteryl Ester Transfer Protein.
Transcription Factor Control
Transcription factors comprise a family of structurally-related eukaryotic proteins 
that are involved in the control of a large number of normal cellular and organismal 
processes, such as immune and inflammatory responses, developmental processes, 
cellular growth, and apoptosis. In addition, these transcription factors are persistently 
active in a number of disease states, including cancer, arthritis, chronic inflammation, 
asthma, neurodegenerative diseases, and heart disease. One factor, Nuclear Factor Kappa-
15
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P (NF-kB), has been implicated in the pathogenesis of both atherosclerosis and diabetes 
mellitus, primarily due to its control of inflammatory gene expression [39]. N F-kB is a 
protein heterodimer, whose activation can be stimulated by a number of factors 
including: high glucose concentrations, free radical formation, TNF-a, radiation and 
other stimuli. Some of the many downstream consequences of NF-kB activation include 
transcriptional synthesis of pro-inflammatory molecules and mediators of their 
expression including: increased expression of adhesion molecules like VCAM-1 and 
ICAM-1, tissue factor (TF) and the receptor for advanced glycation endproducts 
(RAGE). Activation of NF-kB occurs in endothelial cells exposed to high glucose levels 
and low shear stress, but not in endothelial cells which are exposed to hyperglycemia 
without decreased shear flow [40]. Due to decreased shear flow at lesion prone areas, 
increased expression of NF-kB at these sites might persist, leading to the increased 
synthesis of proteins involved in atherosclerotic progression and inflammation including 
VCAM-1. This inflammatory connection, could in part, explain the increased 
atherosclerosis in diabetic patients. Therapeutic control of NF-kB might seem like a 
promising option due to its involvement both in inflammatory control and atherosclerotic 
progression; unfortunately specifically targeting vascular NF-kB is not currently an 
option and complete inhibiton of this gene would have detrimental systemic side effects
[41].
The extensive knowledge of NF-kB signaling also exposes the extent of research 
that still needs to be carried out in order to fully understand the pathway. Overexpression 
studies in-vitro almost certainly do not accurately reflect physiological signaling events, 
and more comprehensive studies looking at clinical endpoints need to be done. Studies in
16
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Drosophila have shown that very small differences in nuclear concentrations of these 
factors, in their affinities for target DNA sites, and in cooperation or competition between 
other transcription factors can have profound physiological consequences [42], In many 
situations, it is not known how or which of the many genes induced by NF-kB in a given 
response contribute acutely to that response. The development of methods to analyze 
genome-scale changes in gene expression (e.g., cDNA microarrays), has already begun to 
uncover additional NF-kB-responsive genes and has helped to clarify which NF-kB target 
genes are activated in a given response. Earlier, unpublished work in our lab, by Gowdy 
et al. established that the combination of a hyperlipidemic and hyperglycemic condition 
in the Syrian golden hamster is associated with increased levels of mediators of 
inflammation, specifically RAGE, VCAM, and NF-kB. This study sought to extend the 
work by Gowdy et al., by determining expression of other inflammatory transcription 
factors and their regulated proteins in the hyperglycemic Syrian hamster.
Peroxisome Proliferator Activated Receptors (PPARs)
Originally discovered as regulators of peroxisome proliferation in rodent livers in 
response to xenobiotics, peroxisome proliferator activated receptors (PPARs) are now 
known as members of the nuclear receptor super-family of ligand-activated transcription 
factors, which also include retinoic X receptor (RXR), and vitamin D receptor [43]. The 
PPARs are among a group of forty-eight nuclear receptors in the human and mouse 
genomes that have been discovered thus far [44]. The nuclear receptors are divided into 
three groups based on the identification of known ligands. In general, these receptors 
contain similar characteristics which include a ligand-independent transcriptional
17
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
activation function domain (AF-1) located on the N terminus, a core DNA-binding 
domain consisting of two highly conserved zinc finger motifs that are responsible for 
binding the receptor to specific DNA sequences, a hinge region that allows flexibility of 
the receptor to dimerize to other nuclear receptors and bind to DNA, a ligand binding 
domain (LBD) and a second dimerization interface, and lastly a second ligand dependent 
activation function domain (AF-2) at the carboxy terminus [45]. The three groups of 
nuclear receptors segregated based on known ligands, their target genes, and their 
physiologic function are: 1) the endocrine receptors, 2) the adopted orphan receptors, and 
3) the orphan receptors. The PPARs are members of the “adopted orphan receptors,” that 
once activated through ligand binding, undergo a conformational change, heterodimerize 
with (RXR), and bind to PPAR response elements (PPRE) in the promoter region of 
target genes, thus modulating genetic expression in either a positive or negative fashion. 
The PPRE consists of a direct repeat of the consensus hexamer AGGCTA separated by 
one or two nucleotides [46,47].
Three subtypes of PPAR exist (a, p/5, and y) encoded on separate genes and 
exhibiting different tissue-specific distributions (See figure 2). PPARa is mainly 
expressed in heart, muscle, kidney and liver; it is responsible for the regulation and 
expression of genes involved in fatty acid oxidation. Fibrates are synthetic ligands of 
PPARa used in the treatment of dyslipidemia, while polyunsaturated fatty acids and 
arachidonic acid metabolites, such as leukotriene B4 are natural ligands of PPARa. 
PPARp/5 is the most ubiquitously expressed of the PPARs and also plays a role in lipid 
metabolism, specifically within cardiac tissue [48]. Of the three subtypes, little is known 
about PPARp/5 and much debate surrounds the role this transcription factor in the
18
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development and modulation of atherosclerosis with strong arguments on both the pro- 
and anti- atherogenic sides. One study reported that treatment of LDL-C -/- mice with the 
potent PPARp/S agonist, GW0742X, reduces atherosclerosis lesion burden, as well as 
expression of pro-inflammatory proteins indicating the beneficial effects of agonizing the 
p/8 receptor in the treatment of atherosclerosis [49]. Further studies assessing the ability 
of PPARp/5 agonists to diminish lesion stability and regress lesion size will provide more 
information in the efficacy of targeting this receptor in treatment of atherosclerosis.
PPARy encodes three major messenger RNAs (mRNAs) resulting from 
differential promoter usage and alternative splicing that results in two different protein 
isoforms differing in a 28 amino acid extension of unknown function at the amino 
terminus [50, 51]. PPARy2 is mainly expressed in adipose tissue, whereas PPARy 1 is 
found ubiquitously, including in the liver, heart, kidney, endothelium, vascular smooth 
muscle cells, and macrophages, as well as other tissues. PPARy has been described as 
having important roles in lipid metabolism, cellular differentiation, atherogenesis, and 
glucose homeostasis[52]. PPARy’s involvement and importance in glucose homeostasis 
is demonstrated by the fact that the insulin sensitizing thiazolidinediones (TZDs) are 
synthetic high-affinity ligands of the PPARy receptor. TZDs are extremely important in 
the treatment of type 2 diabetes due to their ability to promote insulin sensitivity. The use 
of pioglitizone and rosiglitazone, two synthetic PPARy ligands, results in increased 
peripheral glucose use, reduced hepatic glucose output, and improvement in overall 
glycemic control. The activity of PPARs is primarily mediated by the binding of natural 
and synthetic ligands, although its activity is not limited to ligand activation. 
Transcriptional activity of the PPAR receptors can be influenced by other post-
19
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translational modifications such as phosphorylation and ubiquitination [53]. PPARs also 
have the ability to transrepress multiple inflammatory pathways. This transrepression 
involves interaction with coactivators and corepressors including such factors as NFkB, 
AP-1, signal transduction activated transcription factors, CCAAT/enhancer-binding 
protein and nuclear factor of activated T cells. Still today, much work needs to be carried 
out looking at the interactions of PPARy with other inflammatory transcription factors to 
elucidate the pathways involved as well as to uncover future therapeutic targets.
Besides their effects on carbohydrate metabolism and overall glycemic control, 
PPARy ligands have also been to shown to have beneficial effects on plasma lipids, 
important molecules in the progression of atherosclerosis. PPARy is expressed in the 
endothelium [54], macrophages [23], and human atherosclerotic lesions [55] and has 
been shown to be expressed in almost every stage of atherosclerosis development and 
progression (See table 1). As well as being expressed ubiquitously throughout 
atherosclerotic tissue, PPARy agonists have also been shown to have pleiotropic vascular 
effects. When PPARy agonists are administered for the treatment of type 2 diabetes, the 
beneficial affects on cardiovascular disease risk may be attributed to the indirect affects 
on insulin resistance, a direct inhibitory affect on atherogenesis and endothelial cell 
dysfunction, as well as a potent antiinflammatory effect on molecules such as monocyte 
chemoattractant protein-1 (MCP-1) and C-reactive protein (CRP). So, the ability of 
PPARy and its agonists to regulate the atherosclerotic process might potentially be a 
complex, coordinated interaction between the indirect effects of PPARy activation on 
improving insulin sensitivity and reducing inflammation; this effect might also be 
coupled with PPARy’s ability to regulate glucose and fat metabolism.
20
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Figure 2: PPAR Isoforms Adoptedfrom Li et al.[45]
Initial work by Marx et al.[56] brought attention to PPARy and its role in 
atherogenesis. Further work by Marx observed increased expression of PPARy within 
both endothelial cells and vascular smooth muscle cells that were involved in 
atherosclerotic plaques of human coronary arteries [46, 57]. As stated, the initial concept 
was that this inflammatory transcription factor is being activated in all o f the cell types
21
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involved in the development and progression of atherosclerosis. The research began to 
shift towards the reasons why PPARy was being expressed in the human atheroma. The 
following year (1999), Yoshimoto et al. [58], using Wistar rats, clearly demonstrated that 
PPARy ligands are powerful inhibitors of vascular smooth muscle cell proliferation and 
that they may be a target for the treatment of neointimal hyperplasia. In early 2001, 
Collins and associates proposed a mechanism for the atheroprotective effects of PPARy 
and its ligands [59], demonstrating that troglitazone significantly reduced the number of 
macrophages within atherosclerotic lesions in both nondiabetic and diabetic mice. 
Rosiglitazone was also shown to limit lesion formation in LDL-C receptor deficient mice 
[60], and similar results were reported in apoE knockout mice [61]. Therefore, PPARy 
agonists seem to inhibit early lesion formation possibly through interference of monocyte 
transendothelial migration with or without insulin resistance. Because PPARy was able to 
exhibit similar effects in diabetics and nondiabetics, its ligands seem to have separate 
antiatherogenic activities in addition to their insulin sensitizing effects. To further 
elucidate these protective effects and the ability to use PPARy ligands as a therapeutic 
tool, not only for the treatment of type 2 diabetes but also as a prophylactic for the 
progression of atherosclerosis, one needs to asses the ability of PPARy ligands to affect 
clinical endpoints o f atherosclerosis. One of the first clinical studies to evaluate the 
effects of PPARy agonists on atherosclerosis progression was performed using Japanese 
patients living with type 2 diabetes. These patients were treated with either 30 mg/day of 
pioglitzaone or placebo for six months and carotid intima thickness (IMT) was evaluated 
at baseline, three months and six months post-treatment. In the placebo group, IMT 
increased from baseline by an average of about 0.22mm over the six months while
22
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decreasing about 0.084mm in the treatment group. These differences were significant, 
and demonstrated that PPARy agonist treatment could result in early inhibition of normal, 
atherogenic processes[62].
PPARy has also been implicated in the mediation of inflammation and some of 
the key players in the inflammatory process including CRP. It is well established that 
inflammation plays a pivotal role in the atherosclerotic process promoting endothelial 
dysfunction, which triggers a cascade of detrimental processes that lead to the formation 
of the atheroma [63]. In a study carried out by Haffner et al., it was demonstrated that 
after 26 weeks of Rosiglitazone treatment in patients with type 2 diabetes, concentrations 
of mean CRP, MMP-9, and WBC were all significantly decreased [64]. Rosiglitazone 
had similar effects on CRP levels as well as fibrinogen levels in nondiabetic patients in a 
study carried out by Sidhu et al., [62]. Several studies have confirmed that CRP, in 
addition to being a powerful predictive biomarker, is also a mediator of atherosclerosis. 
CRP has been demonstrated to decrease nitric oxide production, destabilize nitric oxide 
synthase mRNA, increase endothelial cell apoptosis and increase NFkB expression [65, 
66]. If CRP expression can be decreased through stimulation of PPARy, so can the 
proatherogenic affects mediated by CRP. However, the debate over the involvement of 
PPARy as well as CRP in the initiation and progression of the inflammatory process is 
still a controversial one. As stated, PPARy is expressed in vascular smooth muscle cells, 
endothelial cells, macrophages and T cells, all integrally involved in the inflammatory 
cascade. The debate is not over whether or not PPARy is expressed in these cells, or even 
whether or not it is involved in the regulation of the inflammatory response; these are 
both accepted concepts. The debate stems from the question of whether or not PPARy is
23
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an anti- or pro- inflammatory mediator. PPARy specific ligands have been shown to 
inhibit the expression of a host of inflammatory cytokines including TNF-a, interleukin 
(IL) 1P and IL6 in monocytes [67], as well as inducible nitric oxide synthase, MMP-9, 
and scavenger receptor 1 in macrophages [68]. In one study, PPARy ligands inhibited 
angiotensin II (Ang II)-accelerated atherosclerosis in LDL-C -\- mice, whereas there was 
no effect on lipid profiles, blood glucoses, or blood pressure. Intriguingly, the attenuation 
of Angll-accelerated atherosclerosis was correlated with a down regulation of the 
proinflammatory transcription factor early growth response gene 1 (Egr-1) and several of 
its target genes [69]. Due to the observation that while blood pressure and glycemic status 
were unaffected, but progression of atherosclerosis was inhibited, one can tentatively 
conclude that inhibition of inflammation plays a crucial role in the anti-atherosclerotic 
affect of PPARy ligands. Further work elucidating some of the mechanisms behind the 
antiinflammatory affects of PPARy as well as clinical endpoints of atherosclerosis needs 
to be carried out in order to characterize PPARy’s effect on inflammation and how its 
regulation of inflammation affects progression of atherosclerosis. Large-scale trials 
examining the effects of PPARy ligands on clinical cardiovascular endpoints are 
underway, but data is currently being collected from smaller clinical studies in patients 
with type 2 diabetes. One such study demonstrated that troglitazone and pioglitazone 
have potent inhibitory effects on the progression of carotid arterial intima-media 
thickness [70]. Unfortuately, one cannot determine whether the antiatherosclerotic effect 
observed post administration of the insulin sensitivity treatment was independent of the 
antidiabetic effects of the drugs. Hypothetically, the reduction in intima media thickness
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was caused by a combination of the antiinflammatory effects of the PPAR agonists as 
well as the confounding effects of increasing systemic insulin sensitivity.
There is also one general effect of PPARy activation, not yet discussed, that could 
also contribute to a decrease in atherosclerotic progression. Most diabetic patients also 
live with an abnormal lipid profile or chronic dyslipidemia; in addition to endothelial 
dysfunction, atherogenesis, and thrombosis, insulin resistance causes decreased uptake of 
free fatty acids (FFA) by adipocytes [71]. Because of increased systemic FFA 
concentrations, hepatic uptake of FFA also increases, which in turn increases hepatic 
production of triglyceride-rich lipoproteins, such as very low density lipoprotein (VLDL- 
C), resulting in a dyslipidemic state. This increase in VLDL-C is also associated with 
smaller HDL-C particles that are less efficient at the removal of CEs from peripheral 
tissue including the arterial wall and lipid-laden macrophages. A rise in VLDL-C is also 
associated with the smaller, denser more atherogenic LDL-C particles that are more 
susceptible to modification such as oxidation.
The systemic increase in circulating atherogenic lipoproteins and the subsequent 
rapid uptake leading to foam cell formation is the basis of the atherosclerotic disease 
state. As stated earlier, at any time, there is a dynamic between the amount of free 
cholesterol and CEs within the cell. Removal of cholesterol from lipid-laden 
macrophages within the arterial wall theoretically could lead to the regression of 
atherosclerosis or stabilization of the plaque. Stabilization of the plaque could prove 
integral in prophylactically treating patients at high risk o f CVD; primarily because of the 
detrimental results of plaque rupture (stroke, myocardial infarction and all ischemic
25
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diseases). Note the summary below of the effects of PPARy on general processes of 
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Table l:PPARy and Atherosclerosis Derived from Halabi et al.[43]
The involvement of NF-kB, PPARs and other transcription factors in human 
inflammation and disease certainly establishes them as targets for therapeutics. Indeed, 
many common synthetic (e.g., aspirin), and traditional (e.g., green tea, curcumin) 
remedies target, at least in part, the NF-kB signaling pathway. It is likely that our 
knowledge of the molecular details of these pathways will enable us to develop more 
specific and potent NF-kB inhibitors. The power and control of these transcription factors 
in the regulation of the pathology of many disease states is quite evident, which turns us 
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ATP Binding Cassette Transporter Al (ABCA1)
Having the ability to enhance cholesterol efflux from foam cells and facilitate its 
return to the liver for processing could potentially be a target for dug therapy in the 
treatment of atherosclerosis. About 7 years ago, Bodzioch et al. [72] were able to identify 
the molecular defect in Tangiers disease, namely ABCA1. Patients living with Tangier 
disease (TD) present with low levels of HDL-C and increased sterol accumulation in 
macrophages putting them at an increased risk for developing CVD. ABCA1 is a 
membrane transporter abundant in macrophages and expressed ubiquitously that mediates 
the cholesterol and phospholipid (PL) efflux to lipid poor apoAl, the precursor of HDL- 
C, and hence plays a major role in reverse cholesterol transport and general cholesterol 
homeostasis (see figure 3) [73].
Bile
ABCA1 _ £ £LCAT
Liver Mature HDL Nascent HDL Macrophage
Figure 3: ABCA1 in Reverse Cholesterol Transport [74]
CE=Cholesteryl Ester, HDL=High Density Lipoprotein, LDL-C=Low Density 
Lipoprotein, FC=Free Cholesterol, SRBI=Scavenger Receptor B1, ABCA1 =A TP Binding 
Cassette A l , LCAT—Lecithin cholesterol acyltransferase
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The structure of ABCA1 is characterized by the presence of two transmembrane 
domains with six helices each, and a nucleotide binding domain containing two 
conserved peptide motifs that are characteristic for the superfamily of ABC transporters. 
The membrane transporter also contains two large extracellular loops joined by a 
disulfide linkage which are throught to be important in the binding of apoAl. Cholesterol 
efflux from the cell occurs through multiple pathways, ABCA1 being one of them. The 
efflux of FC promoted by ABCA1 is considered to be unidirectional and occurs through 
active transport to apoAl, the most abundant apolipoprotein in HDL-C. Recent work 
suggests that ABCA1 mediates simultaneous transport of FC and PL to apolipoproteins 
based on the availability of different lipoproteins in the vicinity of the transporter itself; 
the local discrimination of ABCA1 may result in modification of the ratio of cholesterol 
/phospholipid undergoing efflux. Recent work has also shown that affecting the 
PL/apoAl ratio could play a major role in directing FC efflux through either the ABCA1 
or the scavenger receptor B1 (SR-B1) pathway[75]. The apoAl concentration in the 
extracellular fluid is dependent on synthesis, catabolism, and dissociation. ApoAl’s 
availability is also dependent on its reassociation with the lipoproteins in the plasma 
compartment represented by the HDL-C fraction, which in turn could potentially 
influence lipid efflux from the atheroma.
As stated earlier, the atherosclerotic plaque is a dynamic, multi-factorial 
environment in which multiple mechanisms can affect its’ progression and stabilization. 
Some of these mechanisms that may be directly modified by the activation of ABCA1 
include: altered extracellular matrix turnover, lipid accumulation and metabolism, and 
alterations in cell turnover involving apoptosis and inflammation. Apoptosis, or
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programmed cell death, plays an important role in regulating and controlling cellular 
turnover within atherosclerotic plaques. In order for the apoptotic process to be 
successful as well as immunologically silent, the initial phase must be followed by an 
efficient phagocytic phase. After initiation, phosphotidylserine (PS), an anionic 
phospholipid which resides on the inner leaflet, is translocated to the outer leaflet which 
allows the dying cell to be recognized by the phagocyte. ABCA1 was found to be 
involved in promoting PS translocation and subsequent engulfment of the apoptotic cells 
[76], This work illustrated that phagocytosis is impaired in ABCA1 deficient 
macrophages and that forced induction of ABCA1 can cause engulfment by cells 
normally not able to carry out the phagocytic process. The ability of ABCA1 to regulate 
the apoptotic process, or at least induce the removal of dead cells that have undergone 
apoptosis, presents a possible mechanism that can be targeted for the prevention of 
progression and/or regression of the plaque. Advanced atherosclerotic plaques contain 
high numbers of necrotic or dead cells, and enhancing the body’s ability to remove those 
cells could aid in decreasing title severity of the atheroma.
Since ABCA1 also plays a putative role in inflammation, it may be involved in 
the pathophysiology of atherosclerosis. A number of inflammatory mediators including 
interferon-gamma (IFN-y), TNFa, and IL-1 have been reported to decrease the mRNA 
and protein expression levels of ABCA1. It has been demonstrated that IFN- y can cause 
a 3-fold downregulation of ABCA1 while simultaneously increasing AC AT activity, thus 
promoting atherosclerosis. Also, IL-lp, an activator of matrix metalloproteinases 
(MMPs) and other interleukins have also been reported to inhibit ABCA1 function thus 
inducing cellular lipid accumulation [77], Although the role of ABCA1 in the transport
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and expression of the pro-inflammatory cytokines still needs further elucidation, it could 
be speculated that a detrimental cycle might exist in which the initial activation of 
macrophages and stimulation of cytokine release could cause ABCA1 deficiency. This 
“relative deficiency” of ABCA1 could potentially lead to decreased clearance of 
apoptotic and necrotic cells which in turn could further aggravate inflammatory 
mediators leading to plaque instability. Based on its antiinflammatory and apoptotic 
properties, therapeutic regulation of ABCA1 expression could be a promising target in 
the treatment of atherosclerosis [24].
As discussed earlier, removal of peripheral cholesterol from extra-hepatic tissue is 
important in controlling the amount of lipid within the central core of the plaque. The 
process of reverse cholesterol transport is carried out by ABCA1 dependent and 
independent mechanisms. ApoAl that is regenerated from HDL-C, or secreted by the 
liver, is lipidated by ABCA1 in peripheral tissue to form pre-p HDL-C which then can 
collect cholesterol from extra-hepatic cells. It is also thought that cholesterol processed 
from LDL-C uptake in the liver is transferred to HDL-C by hepatic ABCA1 to be 
converted into bile for secretion, a process that is beneficial to atherosclerotic 
progression. In the Framingham Heart Study [78], a 2-3 fold increase in cardiovascular 
disease was observed in TD patients and obligate ABCA1 heterozygotes as compared to 
age and sex matched controls. Another recent study found that patients with ABCA1 
mutations had decreased amounts o f cholesterol efflux, lower HDL-C concentrations and 
greater carotid-intima-media thickness as compared to matched controls [79]. 
Cumulatively, these studies imply a generalized anti-atherogenic effect of ABCA1 via its
30
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
contribution to HDL-C formation while macrophage-bound ABCA1 provides a 
peripheral anti-atherogenic effect on the vasculature.
PPARy and ABCA1: The LXR Connection
As discussed earlier, PPARy can work in concert with corepresssors and 
coactivtaors, binding to DNA response elements in order to initiate a genetic response. 
PPARy can heterodimerize with liver X receptor (LXR), another nuclear receptor 
belonging to the same superfamily as PPARy. The LXR subfamily consists of two 
members, LXRa and LXRp. LXRa is expressed in an auto-regulated and tissue-specific 
manner, whereas LXRp is expressed ubiquitously. The LXRs are regulated (ligand 
bound) by the oxysterols which appear to be produced in proportion to cellular 
cholesterol content [80] and have been shown to play an important role in regulating 
some of the mechanisms that protect cells from increased cholesterol levels. LXRs also 
positively regulate several intestinal and hepatic genes integral in cholesterol excretion 
form the body, including Cyp'7, the rate limiting enzyme in bile acid synthesis as well as 
ABCA1. PPARy can indirectly enhance cholesterol efflux by inducing the transcription 
of LXRa and thus ABCA1. Consequently, the concentration of LXRa expressed in 
macrophages within the plaque is important because of its ability to control ABCA1 
dependent cholesterol efflux. LXRs ability to control cholesterol efflux is completely 
dependent on ligand availability, which can be affected by endogenous homeostasis (i.e., 
increased fatty acids). LXRa has been shown to upregulate sterol regulatory element 
binding protein-1 (SREBP-1) which results in increased unsaturated fatty acid synthesis. 
Unsaturated fatty acids can promote ABCA1 degradation, indicating indirect negative
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regulation of ABCA1 by LXRa [80]. This might not seem important, but could prove to 
be in patients with insulin resistance and type 2 diabetes where increased levels of fatty 
acids are observed. This degradation of ABCA1 could in turn be counteracted within the 
atherosclerotic plaque due to the oxysterol-rich environment which would activate LXRa 
thus upregulating ABCA1. PPAR agonists, like the glitazones used in the treatment of 
type 2-diabetes, have been shown in vitro to induce cholesterol efflux from macrophages 
through the activation of ABCA1[81]. This control, interestingly, overrides the 
inflammatory suppression of ABCA1 by the cytokine IL-1(1 [77]. In terms of plaque 
physiology, this could prove to be very important due to the increase in inflammatory 
signals observed within the atheroma. Taken together, therapeutic regulation of PPARy 
could have positive independent and ABCA1 associated effects on the initiation and 
progression of atherosclerotic disease in diabetic and non-diabetic patients.
The purpose of the current study is to examine the effects of hyperglycemia on the 
atherosclerosis caused by diet induced hyperlipemia. The study will investigate one of the 
major transcription factors of inflammation and lipid metabolism, PPARy, and how its 
role in inflammation and reverse cholesterol transport may affect the development of 
atherosclerosis. PPARy expression will be compared to ABCA1, an important trans­
membrane protein involved in the shuttling of cholesterol from peripheral tissue back to 
the liver for processing to determine whether this process is affected by the 
hyperglycemic state.
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Objectives:
1. To determine if hyperglycemia is associated with accelerated atherogenesis as 
indicated by plaque morphology in a hamster model.
2. To determine if the hyperglycemic state is associated with altered levels of expression 
of PPARy in vivo.
3. To determine if expression of hamster ABCA1 is correlated to increased hamster 
PPARy expression in vivo.
4. To determine whether increasing expression of ABCA1 is associated with increasing 
circulating levels of HDL-C in hyperglycemic Syrian hamsters.
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CHAPTER 2
EXPERIMENTAL DESIGN
Forty-six Syrian FIB male hamsters were brought into the animal facilities and 
allowed to acclimate for one week, after which four groups were established. Half of the 
hamsters (23) were given a high fat/high cholesterol diet with streptozotocin (STZ) 
(hyperglycemic/hyperlipemic), while the other half was only fed the high fat diet 
(hyperlipemic). One half of the animals from each group were treated for 8 weeks, while 
the other half were treated for 24 weeks. At each time point, hamsters were sacrificed and 
blood was taken for total cholesterol, blood glucose, HbAlC, triglycerides, HDL-C 
cholesterol and non-HDL-C cholesterol. Tissue was removed at time of sacrifice and 
fixed for immunohistochemical analysis or frozen for Western blot and ELISA analysis 
of ABCA1 and PPARy.
Groups:
1. Hyperlipidemic (8 week Control)
2. Hyperglycemic/Hyperlipidemic (8 week Treatment)
3. Hyperlipidemic (24 week Control)
4. Hyperglycemic/Hyperlipidemic (24 week Treatment)
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The FIB Syrian golden hamster (Mesocricetus auratus), as an animal model of 
atherosclerosis, presents some unique characteristics that are normally unachievable in 
other rodent models [82], Hamsters, when fed an atherogenic diet, develop predictable 
lesions along the inner curvature of the aortic arch in a pathology similar to humans. One 
hamster study observed fatty streak lesions developing within four weeks of the start of 
an atherogenic diet and determined that the lesions were morphologically and 
ultrastructurally similar to human fatty streak lesions [83]. Similar analyses of hamster 
atherosclerosis have concluded that the lesion development in hamsters progresses 
through similar stages of progression as compared to humans [84, 85]. Another advantage 
of the hamster is that the serum cholesterol level increases observed on the atherogenic 
diet corresponded to an increase in LDL-C and VLDL-C concentrations. This increase is 
attributable to the fact that, in hamsters, LDL-C is the major plasma cholesterol carrier, 
which is similar to humans [86]. This increase in LDL-C is not associated with an 
increase in plasma HDL-C, concomitantly raising their TC/HDL-C ratio. Appropriately, 
an elevated LDL-C value and a high TC/HDL-C ratio are both significantly associated 
with the accelerated atherosclerosis seen in humans and the hamster on atherogenic diets 
[83], From a practical standpoint, the hamsters are also inexpensive and relatively easy to 
handle and care for.
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By administering STZ, a pancreatic P-cell toxin, the hamster has also been used to 
study disease associated with a diabetic-like state [87, 88]. Briefly, STZ methylates DNA 
and generates free radicals ultimately leading to the destruction of the P-cells of the 
pancreas, responsible for the production of insulin. The STZ Syrian FiB hamster on a 
high fat/high cholesterol (atherogenic) diet offers the ability to study the effects of 
hyperglycemia on the development and pathology of atherosclerosis. STZ has been used 
to induce a diabetic state in other animal models including the rat and pig [89, 90], but 
due to their similarities to humans in both lipid profile and metabolism, the hamster may 
be a more appropriate model to study the connections between diabetes, altered lipid 
metabolism and accelerated atherosclerosis. The advantage of the hamster was seen in a 
study by Wang et al. in 2001, in which male Syrian Golden hamsters on a high fat diet 
were given STZ to induce hyperglycemia. After just two weeks, free fatty acids (FFA), 
triglycerides and glucose levels all dramatically increased; serum triglyceride was 
increased by 7.3 fold, FFA by 4.2, and glucose levels by 91% [82], Due to their 
similarities in the initiation and progression of atherosclerosis, both physiologically and 
anatomically, the hyperglycemic hamster provides a unique model in which to study 
human atherogenic progression in a hyperglycemic state.
Animals
Forty-six Syrian FjB male hamsters about 8 weeks in age were purchased from 
BioBreeders Inc. (Fitchburg, MA) and delivered to the laboratory animal research facility
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at the University of New Hampshire. The hamsters were housed individually in plastic 
rodent containers with ad libitum access to rodent chow (Purina 5001) and water and 
maintained on a 12 hour light and dark cycle at 20+ 1° C. Following a one week 
acclimation period, hamsters were randomly assigned to one of the four groups 
1) 8wk control (C), 2) 8wk treated (T), 3) 24wk control (C) or 4) 24wk treated (T). 
Following the one week acclimation, all hamsters (N=46), were fed Purina 5001 rodent 
meal supplemented with 0.25% purified cholesterol (w/w) (Research Diets, Inc., New 
Brunswick, NJ) and coconut oil 10% (w/w) (Spectrum Organic Products, Inc., Petaluma, 
CA). The treated hamsters (N=23) were also given an intraperitoneal (IP) injection of 
STZ (20mg/kg of body weight) (Sigma Chemical, St. Louis, MO) freshly prepared in 
0.1M citrate buffer (pH 4.5) with a 22-gauge needle on a 3cc syringe (Becton Dickinson 
& Co., Rutherford, NJ) one week after arrival at the animal facility. One week after the 
STZ injection, hamsters were started on their respective diets and continued on those 
diets for the duration of the study (8 or 24 weeks). All experimental protocols were 
approved by the Animal Care and Use Committee of the University of New Hampshire 
(IACUC approval: 040706).
At sacrifice, hamsters were anesthetized using a closed chamber containing 
isoflurane (Abbot Laboratories, North Chicago, IL). Once the hamsters were immobile, 
they were removed from the chamber and anesthesia was maintained with a nose cone. 
Foot reflex and jaw tone were checked to ensure that the animals were deeply 
anesthetized. The abdomen was rinsed with 70% alcohol and an incision was made in the 
abdomen through the peritoneum. The ribs were cut to the left of the sternum and 
hemostats were clamped to the edges of the sternum to expose the heart. Blood was
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drawn from the left ventricle of the heart with a 22-gauge needle on a 3cc syringe 
(Becton Dickinson & Co., Rutherford, NJ) and immediately placed into 1.3ml tubes 
containing 35 I.U. of heparin (Sarstedt, Newton, NC). A small drop of whole blood 
(~50uL) was used to measure HbAlC and blood glucose levels prior to aliquoting the 
remaining sample. The samples were then inverted and centrifuged for 12 minutes at 
1,500 x g in a table top Eppendorf 5415 microfuge (Brinkman Instruments, Inc., 
Westbury, NY). Following centrifugation, plasma was aliquoted into microtubes 
(Sarstedt, Newton, NC) and placed on ice. The samples were stored in a -80° C freezer 
(Revco Scientific Inc., Asheville, NC) until analysis.
Following the cardiac puncture, a small incision was made in the right atrium for 
blood outflow, and a 21 gauge 1 inch butterfly needle was inserted into the left ventricle 
to perfuse the circulatory system. Phosphate buffered saline (PBS) pH 7.4 was 
continuously infused into the I.V for five minutes at physiologic pressure (110 mm Hg). 
The fixed hamsters were then perfused for 10 minutes at physiologic pressure with 
neutral buffered formalin (NBF). All hamsters were then placed on ice until dissection. 
Both the aortas and the hearts were carefully removed from the formalin fixed hamsters. 
During dissection, excess adventitia was removed from the aortas to prevent interference 
during protein analysis. The heart and aorta were kept in-tact, and pinned at in-situ length 
overnight in 10% NBF. After overnight fixation, the NBF was removed, and the aortic 
arch was sectioned into three equal pieces (A, B, and C) (figure 5). Each section was 
placed in a labeled, padded plastic tissue cassette to preserve morphology and rinsed in 
ddH20 to wash tissue sections followed by storage in 70% alcohol until processing. 
Sections were sent to the New Hampshire Veterinary Diagnostic Laboratory (NHVDL)
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where they were dehydrated in 100% EtOH and infiltrated with Paraplast Plus ™ 
embedding medium (Oxford Labware, St. Louis, MO) in the Tissue-Tex Automatic 
Tissue processor (Miles Inc., Diagnostic Division, Tarrytown, NY) overnight. After 
embedding in paraplast, each tissue section was trimmed and sectioned into 6 micron 
slices and mounted onto Superffost/Plus glass slides (Fisher Scientific, Pittsburgh, PA) 
for immunohistochemcial analysis.
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Figure 5
Segments of the Hamster Aortic Arch
Heart
Segments o f  the hamster aortic arch: A, B and C are proximal, mid and distal sections 
respectively. Sections B (mid section) was used for immunohistochemical and 
histological evaluation and sections A, B and C were used for ELISA and Western Blot 
analysis.
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Immunohistochemistry
Histologic sections from the B or mid portion between the two carotid arteries 
from each treatment group were incubated with polyclonal antibodies against the antigens 
for PPARy (GENE-TEX, San Antonio, TX) and ABCA1 (ABCAM, Cambridge, UK). 
The PPARy antibody was generated in rabbits against a recombinant protein 
corresponding to C-terminal amino acids 484-498 of PPARy 2. The ABCA1 antibody 
was also generated in rabbits against a synthetic peptide: AETSDGTLPAP, 
corresponding to amino acids 1201-1211 of human ABCA1. Reactivity was visualized 
using the VECTASTAIN® Elite ABC Kit (Vector Laboratories, Burlingame, CA) for 
both ABCA1 and PPARy. Briefly, slides were deparaffinized for 20 minutes in two 
separate toluene baths (10 minutes each), then moved into a series of graded alcohols (10 
minutes in 100% ethanol, 10 minutes in 95% ethanol), and re-hyrdrated in deionized 
water for 10 minutes followed by a five minute rinse in PBS. Sections were then 
incubated (for five minutes) in 3% hydrogen peroxide (American Procurement and 
Logistics Co., Salt Lake City, UT) to eliminate endogenous peroxidase activity, followed 
by a 5 minute rinse with PBS. Slides were than incubated at 80°C for 10 minutes with 
Vector Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA) to aid in 
antigen retrieval. Nonspecific binding was blocked using normal horse serum provided 
by the VECTASTAIN kit in a 10 minute incubation. Excess serum was blotted using a 
Kimwipe™ and tissue sections were incubated overnight (18hrs) at 4°C. Serial dilutions 
were performed in order to determine optimal primary dilutions for both ABCA1 and 
PPARy; dilution was selected following microscopic evaluation of staining intensity and 
background. All dilutions were prepared in PBS with 1% BSA and optimal
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concentrations chosen were; PPARy, 1:500 and ABCA1: 1:50. Optimal primary and 
secondary dilutions were determined through preliminary work carried out on practice 
tissue and were chosen based on signal intensity and minimal background appearance.
For negative controls, aortic tissue from the hyperglycemic/hyperlipidemic group was 
used. The treatment tissue was used because we anticipated a stronger antigenic signal as 
compared to the controls. Negative controls were assessed using PBS, with 1% BSA in 
lieu of the primary antibody. After overnight incubation, slides were washed for 5 
minutes in PBS followed by a 30 minute incubation with provided biotinylated secondary 
antibody (VECTASTAIN kit). Slides were rinsed for five minutes in PBS, followed by 
application of an avidin and biotinylated horse radish peroxidase macromolecule complex 
for 5 minutes followed by another 5 minute rinse in PBS. For visualization of reactivity 
between the protein of interest and the corresponding primary antibody, the chromagen 
3’-amino-9-ethylcarbazole (AEC) (Vector Laboratories, Burlingame, CA), which forms a 
reddish color upon oxidation by horse radish peroxidase, was applied to the slides for 6 
minutes followed by a 5 minute rinse in distilled water. Slides were counter stained with 
undiluted Gil’s hematoxoylin for 30 seconds, (Vector Laboratories, Burlingame, CA) 
rinsed under a gentle tap water stream, and immediately mounted with a glass coverslip 
and aqueous mounting medium (Zymed, San Francisco, CA).
For morphological examination, B (mid) sections were stained with hematoxoylin 
and eosin (H and E) following deparaffinization and rehydration by the New Hampshire 
Veterinary Diagnostic Laboratory. Briefly, H and E staining allows for morphologic 
examination through counterstaining between the nuclei and the cytoskeletal network; 
hematoxoylin stains the nucleic acids (nuclei) blue and the eosin stains the cellulafr
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protein (cytoplasm) pink. All slides were examined and photographed using an upright 
Olympus BH-2 light microscope attached to a digital camera (Qlmaging Corp, Burnaby, 
Canada). Images were printed using a 7600 series Hewlett Packard printer (Hewlett 
Packard Houston, TX) on Canon photo-quality printer paper (Canon, Tokyo, Japan).
Western Blot Protein Analyses
The fixed hearts, aortic arches, and descending aortas and hearts of the hamsters 
were dissected and removed from the animal at the time of sacrifice. Any excess blood 
was flushed with PBS and connective tissue was trimmed to avoid background signal. 
The aortas to be cryo-preserved were cut away from the heart using a sterile razor blade 
at the point of attachment and placed into separate cryo-vials, flushed with nitrogen, 
capped and snap frozen in liquid nitrogen. Frozen tissue sections, including aortas were 
stored at -80° C (Revco Scientific Inc., Asheville, NC) until western blot and 
transcription factor analyses were performed.
To determine expression of specific proteins within the lesion prone area on the 
inner curvature o f the aortic arch, the thoracic aorta was removed from the heart with a 
clean razor blade. The descending thoracic aorta was removed from the arch in line with 
where the proximal portion of aortic arch ended. Western blot analyses for protein 
expression of PPARy were performed on 1 aorta from each treatment group to confirm 
expression. Aortas were processed and extracted on ice in the cold room at 4° C. To 
remove excess blood the lumen of the aortas were flushed with PBS using a ICC syringe. 
The aortas were minced using a cross-hatch pattern with two clean razor blades on glass 
slides coated with aminoalkylsilane (Sigma Diagnostics, St.Louis, MO) to prevent tissue
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and protein adherence. After mincing, the aortic tissue was moved to a plastic microfuge 
tube containing 500uL tris buffered saline (TBS) with protease and phosphatase inhibitor 
mixture (Pierce, Rockford, IL). The aorta was then homogenized with a hand held Tissue 
Tearor (Dremel, Racine, WI) set at level 30 for 3,15 second homogenizations with the 
sample remaining on ice throughout the procedure. Following homogenization, samples 
were kept on ice for 30 minutes, vortexing every five minutes. After homogenization, 
samples were pelleted by centrifugation at 500 x g for 3 minutes and supernatant was 
removed exposing the dry cell pellet in preparation for nuclear extraction. Nuclear 
extraction was performed using the NE-PER nuclear and cytoplasmic Extraction kit 
(Pierce, Rockford, II). Briefly, after concentration of the cell pellet, cytoplasmic 
extraction reagent (CER) was added to the samples and vigorously mixed by vortexing at 
the highest setting. After allowing the sample to incubate with the CER, samples were 
centrifuged at 16,000 x g for five minutes and the supernatant fraction (cytoplasmic 
fraction) was transferred to a clean, pre-chilled tube. The insoluble pellet, which now 
contained nuclei, was vigorously mixed with the nuclear extraction reagent by vortexing 
and allowed to incubate for 40 minutes. The samples were then centrifuged at 16,000 x G 
for 10 minutes, and the supernatant (nuclear extract) fraction was transferred to a clean, 
pre-chilled tube and stored at -80 °C until processing. To concentrate tissue samples, 
aortic tissue was centrifuged, using a 10,000 molecular weight Microcon® centrifugal 
filter tube device (Millipore Corporation, Bedford, MA), at 13,000 x G for 20 minutes at 
4° C. Retentate was then collected via centrifugation at 1,000 x G for 3 minutes at room 
temperature (RT). The protein concentrations of each sample were determined using the
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bicinchoninic acid assay (BCA) (Pierce, Rockford, U) at 450 nanometers on the ELX800 
plate reader (BIO-TEK, Inc., Winooski, VT).
Following protein extraction and quantification, electrophoresis of the proteins 
was conducted. Equal amounts of total protein were loaded into each lane of every gel for 
all the aortic samples. The total amount of protein loaded for PPAR and ABCA1 was 
approximately 7.0ug. Each sample was diluted 1:1 with 2X sample buffer (,5M Tris- 
HCL, 10% sodium dodeclysulfate, 10% 2-mercaptoethanol, 20% glycerol and 0.02% 
bromophenol blue) and incubated for 5 minutes in a water bath maintained between 95- 
100°C. Positive controls, including 3T3 cell extract (Santa Cruz Biotechnology, Santa 
Cruz, CA), and mouse liver lysate (Santa Cruz Biotechnology, Santa Cruz, Ca) were used 
for PPARy. Samples were allowed to cool to RT and centrifuged to collect condensate 
prior to loading. 10 uL of each sample was loaded onto 10% tris-HCL gels (Bio-Rad 
Laboratories, Hercules, Ca). One lane each of Cruz Marker molecular weight markers (5 
uL) (Santa Cruz Biotechnology, Santa Cruz, Ca) and Pierce pre-stained marker (5 uL) 
(Pierce, Rockford, II) were also loaded onto each gel. A volume of 15 uL of 3T3 cell 
lysate and mouse liver lysate was loaded onto the gels. Gels were electrophoresed using 
the Mini-PROTEAN Cell II® system(Bio-Rad Laboratories, Hercules, Ca) for about 50 
minutes at 200 volts (Pharmacia Biotech, Uppsala, Sweden). Filter paper, pads and 
nitrocellulose membranes (Bio-Rad Laboratories, Hercules, Ca) were equilibrated in cold 
Towban buffer (25mM Tris, 192 mM glycine, 20% methanol, pH 8.3) for 15 minutes. 
Protein transfer was performed for one hour at 100 volts (Pharmacia Biotech, Uppsala, 
Sweden). Nonspecific binding was blocked by incubation of blots for one hour in 10% 
(w/v) nonfat dried milk (Santa Cruz Biotechnology, Santa Cruz, Ca) in TBS (lOmM Tris-
46
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
HCL, 150mM NaCl, pH 7.4) containing 0.05% (v/v) Tween-20 (TBST) (Bio-Rad 
Laboratories, Hercules, Ca) on an orbital shaker set between 50-60 rpms at RT. Blots 
were incubated overnight with primary antibody diluted in 10% (w/v) nonfat dried milk 
in TBST at 4°C. Optimal primary and secondary dilutions were determined through 
preliminary work carried out on practice hamster aortic tissue and were chosen based on 
signal intensity and minimal background appearance. Specifically, goat anti-rabbit 
PPARy (GENE-TEX, San Antonio, TX) was made up at a dilution of 1:1000 in 10% 
(w/v) nonfat dried milk in TBST. After overnight incubation with primary antibody, blots 
were washed with a 50ml TBST rinse, followed by 6, 5 minute TBST rinses on an orbital 
shaker set at 60 rpms. Secondary antibody was diluted with 10% (w/v) non fat dried milk 
in TBST at the following dilution; 1:10,000 for PPARy (donkey anti-goat 
immunoglobulin G (IgG)- horseradish peroxidase (HRP), Santa Cruz Biotechnology, 
Santa Cruz, Ca). Blots were incubated with secondary antibody for one hour at RT on an 
orbital shaker. After incubation, 5, 5 minute 100ml rinses with TBST were performed 
followed by one more rinse with TBS to minimize background signal during 
development. West Pico chemiluminescence (Pierce, Rockford, IL) was applied at lOmls 
per blot and incubated for 5 minutes. Blots were wrapped in Saran Wrap™, exposed to 
CL-Xposure Film (Pierce, Rockford, IL) and the film was developed using a Konica 
SRX-101 automated developer.
PPARy Transcription Factor Assay (ELISA)
In order to confirm expression and assess relative concentrations of PPARy, a 96 
well enzyme-linked immunosorbent assay (ELISA) (Cayman Chemical, Ann Arbor, MI)
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was used with the nuclear extracts obtained from the aortic tissue. A specific double 
stranded DNA (dsDNA) sequence containing the peroxisome proliferator response 
element (PPRE) was immobilized on to the bottom of wells of a 96 well plate. Activated 
PPARs contained within the nuclear extract, bind specifically to the PPRE. PPARy is 
detected by the addition of a specific primary antibody directed against PPARy. A 
secondary antibody conjugated to HRP is added to provide a sensitive, colorometric 
reading of absorbance at 450nm. Because the assay was dependent on the binding of 
PPARy to its corresponding response element within the well, the assay specifically 
measured concentrations of active, bound PPARy. The specificity of the assay was 
confirmed using non-specific binding (NSB) wells to confirm antigen specificity, 
clarified cell lysate positive control wells, and competitive double stranded DNA (cDNA) 
wells. Briefly, complete transcription factor binding assay buffer (CTFB) was prepared 
with ddH20, provided assay buffer, and 300mM dithiothreitol (DTT). To the blank wells, 
and NSB wells, lOOul of CTFB was added, while 90uls was added to the sample and 
positive control wells, and 80ul was added to the cDNA wells. Following addition of the 
CTFB, 10 ul of competitor dsDNA was added to the cDNA wells followed by 10 ul of 
the provided positive control which was also added to the positive control wells. lOul of 
each sample was then added to the respective wells, and the plate was allowed to incubate 
overnight at 4°C. The next day, following a series of washes with provided wash buffer 
which contained Tween 20 (.5ml/L), primary (1:100) and conjugated secondary (1:100) 
antibodies were added to all the wells, except for the blanks, and allowed to incubate for 
one hour at room temperature. Finally, lOOul of developing solution was added to all 
wells and allowed to incubate with gentle agitation at RT for 45 minutes. Before reading
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absorption levels, lOOul of stop solution was added to halt the reaction. The plate was 
then read at 450 nanometers on the ELX800 plate reader (BIO-TEK, Inc., Winooski,
VT), and results were expressed as both OD4 5o/ug protein and as a percent of the positive 
control value.
Serum Assays
Plasma samples were removed from the -80°C freezer and thawed at RT. The 
following assays were analyzed spectrophotmetrically on a Milton Roy 
spectrophotometer (Milton Roy Compnay, Rochester, NY) in duplicate and duplicate 
results averaged prior to statistical analysis. Total cholesterol was measured using the 
cholesterol oxidase method (Pointe Scientific, Inc., Lincoln Park, MI). Samples that 
exceeded 700 mg/dl were diluted 1:10 with physiologic saline (.9% NaCl) (The Butler 
Company, Columbus, OH), vortexed, reassayed and the values multiplied by 10. This 
was done to bring the measurement into an accurate portion of the standard curve. 
Triglycerides were determined using the glycerol phosphate oxidase method (Pointe 
Scientific, Inc., Lincoln Park, MI). Samples that exceeded 1000 mg/dl were diluted 1:10 
with physiologic saline (The Butler Company, Columbus, OH), vortexed, reassayed and 
the values multiplied by 10 to increase accuracy.
Since lipids can impede the transmission of light and yield falsely high numbers, a 
‘blank’ of the lipemic samples was prepared by mixing physiologic saline in lieu of assay 
buffer with the plasma sample. After the blank was determined, the value was subtracted
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from the original values obtained in the assay for both the cholesterol and triglyceride 
serum plasma assays.
HDL-C Assay
In order to obtain an accurate concentration of serum HDL-C cholesterol, the 
serum must be combined with a precipitating reagent in order to remove all of the beta 
lipoproteins (LDL-C and VLDL-C). The HDL-C fraction remains in the supernatant 
which is drawn off and treated as a sample to be assayed using the enzymatic cholesterol 
method described above (Pointe Scientific, Inc., Lincoln Park, MI). Briefly, 500 ul of 
hamster plasma was added to 500 ul of the polyethylene glycol precipitating reagent 
(Pointe Scientific, Inc., Lincoln Park, MI), and vortexed thoroughly. The sample was then 
centrifuged for 10 minutes at 2000 x g in a table top Eppendorf 5415 microfuge 
(Brinkman Instruments, Inc., Westbury, NY). Supematent was drawn off and placed in 
respective sample microfuge tubes to be assayed. HDL-C cholesterol was measured using 
the cholesterol oxidase method (Pointe Scientific, Inc., Lincoln Park, MI), and analyzed 
spectrophotmetrically on a Milton Roy spectrophotometer (spectronic (Milton Roy 
Compnay, Rochester, NY) in duplicate and results averaged prior to statistical analysis. 
Samples were standardized to a 50ug/ml HDL-C standard (Pointe Scientific, Inc., Lincoln 
Park, MI).
Statistics
GraphPad Prism version V4.0 for Macintosh (Graph Pad Software, Inc., San 
Diego, California) was used to perform a factorial analysis of variance (ANOVA) 
followed by Tukey’s Multiple Comparison post test to compare groups for all serum
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assays and ELISA results. Data are expressed as the mean + standard error. Values of 
p<0.05 were considered statistically significant.
Photo-documentation
Representative slides from the immunohistochemical analysis were examined and 
photographed microscopically using an Olympus BH-2 microscope at 100X, 200X and 
400X with a digital camera (Qlmaging Corp, Bumaby, Canada) and photo-documented 
using QCapture version 1.2.0. (Qlmaging Corp, Bumaby, Canada). Images were printed 
using a 7600 series Hewlett Packard printer (Hewlett Packard Houston, TX) on Canon 
photo-quality printer paper (Canon, Tokyo, Japan).
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At the beginning of the study, the hamsters weighed an average of 101.6 grams. 
After 8 and 24 week periods, control groups weighed significantly more (p<.0001) than 
their initial weight (Table 2, Figure 5). Although there was a trend of gradually increasing 
weights amongst the treatment groups at 8 and 24 weeks, the differences were not 
significant (p=.1537 for 8 week Tx and p=.4329 for 24 week Tx).
Selection of Hamsters Based on Response to STZ
Hyperglycemia in response to the i.p. STZ injection varies among animals as has 
been documented in previous publications [87, 91]. Studies show a direct relationship 
between HbAlC and average or mean plasma glucose (MPG) levels. For every 1% 
change in human A1C, there is a change of about 35mg/dl in MPG. Due to wide 
variations in MPG and more consistent A1C values, HbAlC levels were used to 
determine the extent of the STZ response. For this study, hyperglycemia was defined as a 
fasting HbAlC of > 6%. The response to the STZ injection, based on elevated HbAlC 
levels was significant as compared to the control groups who did not receive STZ 
injections (p<.0001). Interestingly, the levels in the 8 week controls were significantly 
elevated as compared to the 24 week controls (p<.05), but no difference was observed in
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The 8 week control group had the lowest mean plasma total cholesterol values 
(879.1mg/dL), while the 24 week treatment group had the highest (2474.0mg/dL). 
Compared to the 8 week control animals, plasma total cholesterol values were 
significantly higher (2.6 fold) in the 8 week treatment animals (p<.01). The 8 week 
control values were also significantly lower than the 24 week control values (p<.05) from 
animals that consumed the same diet but for a longer period of time. Although there was 
a trend of higher total cholesterol amongst the 24 week treatments as compared to the 24 
week controls, the differences were not significant (p=.09). Between the 8 and 24 week 
treatment groups, there were no differences and no correlative trends (Table 4, Figure 8).
Mean plasma triglyceride values were lowest for the 8 week control animals 
(707.7mg/dL) and highest for the 8 week treatment animals (3884.0mg/dL) (Table 4, 
Figure 9). The 8 week treatment group had a 5.5 fold increase for mean plasma 
triglycerides compared to the 8 week controls which was a significant difference (p<.01). 
Interestingly, there was almost a 2 fold decrease in the mean plasma triglyceride value in 
the 24 week treatment group as compared to the 8 week treatment group, however, this 
difference failed to reach statistical significance (p>.05). The mean triglyceride level for 
the 24 week treatment group was two fold higher than the value for the 24 week controls, 
but also failed to reach statistical significance (p>.05).
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HDL-C concentrations were lowest in the 24 week treatment hamsters (17.65 
mg/dL) and highest in the 8 week control hamsters (57.63 mg/dL) (Table 5, Figure 10). 
The 24 week treatment hamster values were significantly lower than all other groups 
(p<.01). There was a 2.5 fold difference between the 24 week control and treatment 
values, which were significantly lower (p<.001). Non HDL-C cholesterol values varied 
from group to group, but exhibited an inverse relationship to the HDL-C cholesterol 
values. The mean non HDL-C cholesterol value was 3 fold higher in the 8 week treatment 
hamsters as compared to the 8 week control hamsters (p<01). The 24 week control 
hamsters had a mean plasma non HDL-C cholesterol level of 1,273 mg/dL as compared 
to a level of 2,547 mg/dL in the 24 week treatment hamsters which failed to reach 
statistical significance (p=.08). The 8 week controls had significantly lower non HDL-C 
cholesterol concentrations than the 24 week controls hamsters (p<.05). No significant 
differences were observed when comparing the 8 and 24 week treatment groups. During 
dissection, it was subjectively observed that the serum from both hyperglycemic groups 
(8 and 24 weeks) was far more lipemic than the time matched hyperlipemic (control) 
groups. One commonly used indicator of risk for cardiovascular disease is the ratio of 
total cholesterol to HDL-C cholesterol levels. The 24 week treatment hamsters exhibited 
the highest ratio (140.2), while the 8 week controls had the lowest (15.25) (Table 5,
Figure 11). The 24 week treatment value was significantly higher than the three other 
groups (p<.0001).
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PPARy Expression (ELISA)
A PPARy transcription factor ELISA was performed and analyzed using nuclear 
extracts form hamsters from all four groups. Results were expressed as % positive control 
and as OD4 so/ug protein. No statistically significant differences were observed when 
comparing treatment and controls within time points or when comparing controls and 
treatment groups between time points for PPAR y expression, although presence of active 
PPARy in all four groups was noted (Table 6).
PPARy Expression (Western Blot)
PPARy expression was not detected through Western Blot analysis. Thirty five 
micrograms of positive control (3TC cell lysate) was loaded and presence of PPAR y was 
confirmed, but we were only able to load approximately 6.5ug of total protein (within 
nuclear extracts) for each sample in each lane limiting our ability to confirm expression 
among samples. One possible hypothesis for the lack of reaction seen among sample 
groups was the minimal aortic tissue size, and even more limited protein concentration 
following nuclear extraction.
Histology
Mid or B sections (Figure 5) of the aortic arch were examined to evaluate the 
histology of the aortic wall, and to characterize the stage of lesion development and
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relative size. The sections were processed, sectioned and stained with hematoxylin and 
eosin by the New Hampshire Veterinary Diagnostic Laboratory (Figure 12, N=4).
8 week Control Group: In aortic sections from 8 week control hamsters (n=4) showed 
few to no fatty streak lesions were observed. Normal morphology was observed with a 
continuous monolayer of endothelial cells on top of an intact internal elastic lamina (IEL) 
(Figure 12A).
8 week Treatment Group: Sections of aortic arch from 8 week treatment hamsters (n=4) 
were examined for lesion development. Some early fatty streak lesions were observed 
consisting of 1 to 2 layers of subintimal foam cell formation lining the periphery of the 
luminal space (Figure 12B). The luminal endothelial cell architecture exhibited signs of 
activation although the monolayer and IEL appeared to be intact.
24 week Control Group: In sections of aortic arch form 24 week control hamsters (n=4), 
more advanced fatty streak lesions consisting of clusters of 2 to 4 foam cells, attached to 
the endothelial monolayer, that began to protrude into the luminal space were observed. 
Foam cells present within the lesions appeared to have increased lipid uptake represented 
by increased foam cell cytoplasmic volume (Figure 12C).
24 week Treatment Group: Sections of aortic arch from 24 week treatment hamsters 
(n=4) exhibited more developed and larger fatty streak lesions with clusters of 8 to 15 
larger foam cells. Due to foam cell accumulation, lesions protruded well into the luminal 
space and the nuclei of the foam cells were displaced towards the periphery of the cell. 
Both the endothelial monolayer as well as the IEL appeared to be intact (Figure 12D).
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Immunohistochemistry
Parrafin embedded sections of aortic arch for immunohistochemistry were 
deparaffinized in toulene, rehydrated and reacted with primary antibodies for PPARy and 
ABCA1. Positive immunoreactivity was monitored by the presence of red chromagen. 
Representative samples from each group for PPARy are presented in figure 14, and 
figure 15 for ABCA1. Representative negative controls for each antibody are presented 
in figure 13.
PPARy
In the 8 week control group (Figure 14A), the smooth muscle cells exhibited a 
diffuse immunoreaction for PPARy with dispersed chromagen deposition throughout 
medial and intimal space. PPARy immunoreactivity in the 8 week treated (Firgure 14B) 
hamsters was multi-focal and more intense as compared to the 8 week control hamsters. 
However, the reaction in the treatment hamsters tended to be more localized to the foam 
cells and prominent endothelial monolayer. The 24 week control hamsters (Figure 14C) 
had a mild, focal reaction that was localized to the lesion and endothelial monolayer. The 
24 week treated aortic sections (Figure 14D) exhibited a multi-focal, intense reaction in 
the foam cells and a moderate reaction in the SMCs. Thus, although diffuse staining was 
observed throughout the aortic sections in all groups, the reaction became more intense 
with increasing development of the lesions.
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ABCA1
Immunoreactivity for ABCA1 was present within aortas from all four groups. In 
the 8 week control hamsters (Figure 15A), there was multifocal to diffuse 
immunoreactivity for ABC A 1 within the endothelial and smooth muscle cells. A slightly 
more intense reaction was observed in the 8 week STZ treated hamsters both in the 
endothelial cells and SMCs. The 24 week controls (Figure 15C) had a mild multi-focal 
reaction throughout the tissue section within all tunicae. Intense, diffuse 
immunoreactivity was observed in the foam cells of the 24 week treated hamsters (Figure 
15D), while moderate multifocal chromagen deposition was observed in the SMCs. Thus, 
in 8 week treatment and control sections staining is moderately dispersed throughout the 
endothelial and smooth muscle cell layers. Overall, as fatty streak lesion size increased, 
there was a concomitant increase in immunoreactivity.
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8 week Control 93.9 122.9* 30.9
8 week Tx 104.6 112.9 12.9
24 week 
Control 98.2 130.6* 30.6
24 week Tx 109.5 115.3 15.3
Table 2: Hamster Weights
Values are mean + SEM. Values are analyzed for statistical significance 
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with 
were significantly heavier at the end o f treatment (p<.0001).
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Serum Assays
Group Glucose (mg/dL) HbAlC (%)
8 week Control 289.6 + 34.4a 3.7 + 0.1a
8 week Tx 364.8 + 21.2a 8 + 0.4b
24 week Control 223.4 + 21.2a 3.3 + 0.1a
24 weekTx 328.4 +31.3b 7.1 + 0.4b
Table 3: Plasma Glucose and Hemoglobin A1C
HbAlC = Hemoglobin A1C
Group TC (mg/dL) TRIG (mg/dL)
8 week Control 879.1 + 101.53 705.7 + 88.8a
8 week Tx 2328 + 442.4b 3884 + 1057b
24 week 
Control 1425 + 160.3b 1172 + 93.0°
24 week Tx 2474+ 543.4b 2193 + 791.8°
Table 4: Plasma Total Cholesterol and Triglycerides
TC = total cholesterol, TRIG = triglycerides,
HDL-C Non-HDL-C Cholesterol TC/HDL-C
57.63 + 18.93 807.3 + 110.43 15.25 + .005a
36.36 + 5.6a 2292 + 437.9b 64.03+ .015b
42.94 + 4.0a 1273+ 161.0° 33.19 + .095°
17.65 + 3.3b 2547 + 592.5b 140.17 + .085d
Table 5: HDUnon-HDL Cholesterol and Total Cholesterol/HDL Ratio
HDL-C = high density lipoprotein, TC=Total Cholesterol
Values are mean + SEM. Values are analyzed for statistical significance 
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with 
dissimilar superscripts are significantly different (p<.05).
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Active PPARy Expression (Nuclear Extracts)
N=4
8 week 
Control 8 week Tx
24 week 
Controls 24 Week Tx
Averages (%Positive Control) 8.071 + 0.07 8.348 + 0.05 13.371 + 0.20 7.726 + 0.06
Averages (OD450/ug protein) 0.126 + 0.05 0.13 + 0.04 0.208 + 0.15 0.12 + 0.04
Table 6: Active PPARy Expression (ELISA Results)
Values are mean + SEM. Values are analyzed for statistical significance 
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with 
dissimilar superscripts are significantly different (p<.05).
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Figure 6 
Hamster Weights
Hamster Body Weights at 
Initiation of Study
*v«v»v* v » w
W .'A * .
y«v*v.
8wk 8wk 24wk 24wk 
Controls Treated Controls Treated
Time
Final Hamster Body Weights at 8 or 24 weeks
8wk 8wk 24wk 24wk 
Controls Treated Controls Treated
Time
Values are mean + SEM. Values are analyzed for statistical significance 
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with * 
were significantly heavier at the end of treatment (p<.0001).
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Figure 7
Hemoglobin A1C Values
8wk 8wk 24wk 24wk
Controls Treated Controls Treated
Time
Values are mean + SEM. Values are analyzed for statistical significance 
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with 
dissimilar superscripts are significantly different (p<.05)
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8wk 8wk 24wk 24wk
Controls Treated Controls Treated
Time
Values are mean + SEM. Values are analyzed for statistical significance 
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with 
dissimilar superscripts are significantly different (p<.05).
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Figure 9










8wk 8wk 24wk 24wk
Controls Treated Controls Treated
Time
Values are mean + SEM. Values are analyzed for statistical significance 
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with 
dissimilar superscripts are significantly different (p<.05).
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8wk 8wk 24wk 24wk
Controls Treated Controls Treated
Time
Values are mean + SEM. Values are analyzed for statistical significance 
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with 
dissimilar superscripts are significantly different (p<.05).
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Figure 11
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8wk 8wk 24wk 24wk 
Controls Treated Controls Treated
Time
Values are mean + SEM. Values are analyzed for statistical significance 
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with 
dissimilar superscripts are significantly different (p<.05).
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8wk 8wk 24wk 24wk
Controls Treated Controls Treated
Time
Values are mean + SEM. Values are analyzed for statistical significance 
with an ANOVA with a Tukey’s Multiple Comparison test. Groups with 
dissimilar superscripts are significantly different (p<.05).
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Figure 13. Cross-sections of hamster aortic arch (mid section (B)) at 8 and 24 weeks. No 
lesions were found in the 8 week control sections (A). In the treatment group (8 weeks), 
early fatty streaks consisting of one or two layers of subendothelial foam cells were 
observed (B), as the endothelial cells are rested on a prominent, continuous internal 
elastic lamina. Fully developed fatty streaks were present in the 24 week control hamsters 
(C). In 24 week Hyperglycemic/Hyperlipidemic aortic sections, (D) advanced fatty streak 
lesions consisting of several layers of foam cells were present causing a greater 
protrusion into the luminal space. Again, the IEL remained intact. * indicates localization 
foam cells. Photographed at 200X.
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Figure 14. Cross-sections of hamster aortic arch (mid section (B)) at 8 weeks used as 
negative controls stained for ABCA1 and PPARy. In lieu of primary antibody, arterial 
tissue section was incubated with PBS with 1% bovine serum albumin. (A) is a 
representative negative control for ABCA1, while (B) is a representative negative control 
section for PPARy. Sections were counterstained with Mayer’s hematoxylin. 
Photographed at 200X.
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Figure 15. Cross-sections of hamster aortic arch (mid section) immunoreacted with a 
polyclonal antibody for PPARy. 8-week control (A) had multifocal immunoreaction for 
PPARy throughout endothelial cells and smooth muscle cells of the tunica media. A more 
prominent reaction is observed in the 8-week treatment group (B), with intense 
immunoreactivity infoam cells and endothelial layer. In the 24-week controls (C), there 
was moderate, localized immunoreactivity in foam cells and endothelial layer. The 24 
week hyperglycemic group (D) had a intense, multi-focal reaction in the foam cells and a 
moderate reaction in the medial SMCs. All sections were counterstained with Mayer’s 
hematoxylin. Photographed at 200X.
73
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
74
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 16. Cross-sections of hamster aortic arch (mid section) immunoreacted with a 
polyclonal antibody for ABCA1. 8-week controls (A) had multifocal immunoreaction for 
ABCA1 throughout the endothelium and smooth muscle cells of the tunica media. 
Intense, multifocal to diffuse immunoreactivity for ABCA-1 was evident in the 8-week 
treated group (B) in the endothelial cedis and throughout the tunica media and adventitia. 
The 24 week controls (C) had a mild, multi-focal reaction throughout all tunicae. The 24 
week treatment group (D) had intense immunoreactivity in the foam cells and moderate, 
multifocal immunoreactivity in the tunica media. All sections were counterstained with 
Mayer’s hematoxylin. Photographed at 200X.
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CHAPTER 5 
DISCUSSION
Hyperglycemia, one pathology found in both type I and type II diabetes 
accelerates the process of atherogenesis in both human patients and animal models [92]. 
Although the exact mechanism(s) by which hyperglycemia accelerates atherosclerosis is 
unknown, one possibility may be that the hyperglycemic state effects the activation of 
inflammatory transcription factors involved in atherogenesis and the progression of 
atherosclerosis. Hypercholesterolemia, a major risk factor for atherosclerosis, causes 
focal endothelial activation. When plasma levels of cholesterol-rich LDL-C and VLDL-C 
become elevated, the lipoproteins infiltrate the artery wall to an extent that surpasses the 
capacity for removal causing retention within the extracellular matrix [93]. Inflammatory 
transcription factors, activated upstream, which control genes involved in lipid 
metabolism may accentuate or attenuate this process of cholesterol deposition and 
atherosclerotic initiation. This is an initiating step in atherogenesis, which if controlled, 
could lead to diminished progression of atherosclerosis.
In a hamster model of hyperlipemia and combined hyperlipemia and 
hyperglycemia, we sought to determine how inflammatory transcriptional control 
involved in the development of atherosclerosis would be affected by hyperglycemia and 
if  it would affect the initiation and progression of atherosclerosis. In the FiB strain of 
Syrian golden hamster, feeding a high fat/high cholesterol (atherogenic) diet caused 
atherosclerotic lesion development in a predictable manner, and with a morphology and 
pathology similar to humans [83, 94], In order to create an atherogenic rodent chow,
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0.25% cholesterol and 10% fat was added to the chow (w/w). The atherogenic rodent 
chow contained 23.5% calories from protein, 26.3% calories from fat, 50% calories from 
carbohydrates and 32.4 mg (.27% w/w) cholesterol. Adding fat and cholesterol to the 
rodent chow not only promotes the development of atherosclerosis, it also makes the diet 
more comparable to a typical Western diet. Although the fat and cholesterol content of 
the hamster diet contains 8% less calories from fat than the typical Western diet, and only 
12% of the cholesterol provided by a Western diet, the atherogenic diet correlates more to 
the “typical American diet” than the normal rodent chow. Fat and cholesterol are 
frequently added to rodent chow in order to increase insulin resistance and promote the 
development of atherosclerosis [82,95, 96]. In one study, after feeding an atherogenic 
diet for just ten days, total cholesterol, triglycerides and LDL-C levels were all 
significantly elevated while HDL-C cholesterol decreased in a fashion similar to that seen 
in humans [82]. It is important to note that the levels of LDL-C cholesterol, the major 
plasma cholesterol carrier in both the hamster and humans was significantly elevated 
making them more prone to developing atherosclerosis. Hyperglycemia can also be 
induced in the Syrian golden hamster through administration of STZ. The hyperglycemic 
hamster fed a high fat diet provides a unique model to investigate atherosclerosis under 
“diabetic-like” conditions [87, 90].
With exception of the 8 week control hamsters, all other groups exhibited fatty 
streak lesion development to varying degrees. In a few hamsters, occasional clusters of 
foam cells were present, however, in most of the 8 week controls no foam cells or cell 
pathologies were visible in any of the aortic sections, and it appeared that the hamsters 
maintained normal endothelial morphology. In the 8 week treatment hamsters, the
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endothelial cell architecture was beginning to become more prominent, a sign of 
activation, although the monolayer and IEL seemed to be intact. At 8 weeks, the 
hyperglycemic hamsters exhibited early fatty streak lesions, consisting of 1 to 2 layers of 
subintimal foam cell formation, as has been previously described [83]. The presence of 
early fatty streak lesions in the 8 week treatment hamsters as compared to the 8 week 
control hamsters suggested that, even at early stages, hyperglycemia, elevated TG, TC or 
perhaps all three accelerated atherogenesis in this lipemic hamster model. These 
morphological differences in lesion development were more pronounced in the 24 week 
hamsters. The 24 week control hamsters had more extensive mature fatty streak lesions 
that protruded into the vessel lumen while the 24 week treatment hamster, due to 
increased lipid uptake, exhibited lesions that protruded into the luminal space with foam 
cell nuclear displacement. Once again, due to differences in lesion development between 
the 24 week groups, it appeared that the hyperglycemic conditions and associated altered 
lipid levels were accelerating lesional progression. To see if the different conditions 
would affect levels of transcriptional regulators of inflammation, immunohistochemistry 
(IHC), western blot (WB) and ELISA analyses were performed for the two proteins 
PPARy and ABCA1 which are both associated with lipid metabolism and atherogenic 
progression [24, 80].
In this study, the 8 week treatment hamsters had significantly higher total 
cholesterol values than their time matched controls (p<.01) placing these hamsters at 
greater risk for developing atherosclerosis. A similar trend was observed for total 
cholesterol values amongst the two 24 week groups, although the difference failed to 
reach statistical significance (P>.05). This discordance could be attributed to the extreme
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hyoerglycemic state (based on elevated BG and HbAlC levels) induced in the 24 week 
treatment hamsters leading to hypophagia. This decrease in total cholesterol was 
associated with a concomitant decrease in HDL-C cholesterol exhibiting a possible 
reason why these diabetic hamsters might have an increased risk for developing CVD. 
Interestingly, the molar concentration of HDL-C, which contains relatively more protein 
and phospholipid than LDL-C, is similar to that of LDL-C in the plasma and, because of 
its smaller particle size, HDL-C is the predominant lipoprotein species in the tissue. Also, 
it has been shown in older men and women of any age that the inverse relationship of 
CHD risk with HDL-C is generally stronger than the direct relationship with LDL-C [97]. 
By assessing fluctuations in HDL-C levels in diabetic patients, physicians may be able to 
assess the level of risk for developing cardiovascular disease. HDL-C levels in the 24 
week hyperglycemic hamsters were significantly lower than all of the other hyperlipemic 
hamsters providing a possible reason for increased CVD risk amongst diabetic patients. 
Clinically, physicians often not only rely on levels of total cholesterol and HDL-C 
cholesterol as indicators of CVD risk, but also the ratio between the two[98]. The 
TC/HDL-C ratio followed the expected trend for CVD risk, as it was highest in the 24 
week treatment hamsters and lowest for the 8 week control hamsters. The elevated 
TC/HDL ratio in the 24 week treatment hamsters provides further evidence for the added 
adverse effect of hyperglycemia over time. Plasma triglyceride levels were significantly 
elevated in the 8 week treatment hamsters as compared to the 8 week controls, an 
expected result in individuals with diabetes [2]. Fasting plasma triglycerides were also 
significantly elevated in both 24 week groups as compared to the 8 week controls, 
exposing them to an increased risk of developing atherosclerosis [38, 99]. This increased
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risk associated with elevated triglyceride levels may be attributed to the fact that 
triglyceride-rich VLDL contribute to the formation of small, dense, atherogenic LDL-C 
particles. These dense LDL-C particles are not readily cleared by LDL-C receptors 
causing them to remain in circulation and within peripheral tissue where they are more 
susceptible to oxidative modification [100]. The hypertriglyceridemic state observed in 
the hyperglycemic hamsters contributes to the formation of atherogenic LDL-C through 
increased transfer of cholesterol to LDL-C. Additionally, high triglyceride levels increase 
VLDL-C secretion form the liver resulting in the exchange of TGs from VLDL-C for 
cholesterol esters in HDL-C. The triglyceride in the HDL-C particle can be hydrolyzed, 
which reduces particle size and can affect the binding of the associated HDL-C protein, 
ApoA-1. Once affinity for ApoAl is decreased, it may dissociate from HDL-C where is 
susceptible to metabolism by the kidney [100]. This mechanism contributes to the low 
levels of HDL-C observed in diabetics with elevated triglycerides [38, 99]. To 
summarize, elevated triglycerides leads to the formation of atherogenic LDL-C and 
decreased HDL-C concentrations putting the hyperglycemic hamsters at in increased risk 
for developing atherosclerosis; this implies that elevated glucose alone can not explain 
the increased risk.
An intraperitoneal injection of STZ was used to induce hyperglycemia in both the 
8 and 24 week treatment groups. STZ is a pancreatic |3-cell toxin that causes necrosis or 
marked degenerative changes in the pancreatic P-cells with nuclear pyknosis and 
cytoplasmic vacuolization. It has been shown to produce diabetes mellitus in various 
species including the Syrian hamster [101,102]. Interestingly, most species have a high 
acute mortality to the STZ injection, whereas the Syrian hamster exhibits a high survival
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rate from STZ induced hyperglycemia [103]. STZ is a methylnitrosurea that is taken in 
by rodent P-cells possibly by a glucose transporter molecule. In cells, STZ toxin is an 
alkylating which causes DNA strand breaks activating poly(ADP-ribose) synthase and a 
subsequent lethal deletion of p-cell nicotinamide adenine dinucleotide (NAD). Previous 
studies have also attributed the P-cell breakdown to oxidative stress through the 
formation of reactive oxygen species (RQS); this effect is further amplified by low levels 
of antioxidant present within P-cell DNA [104], Regardless of the mechanism involved, 
the result of STZ injection is elevated blood glucose levels as a result of DNA strand 
breaks that are lethal to the insulin producing P-cells.
STZ treatment successfully induced a state of hyperglycemia in both 8 and 24 
week treated groups. This effect was evident by the significant increase in fasting HbAlC 
levels in these groups as compared to the control (hyperlipemic) hamsters (p<.0001). The 
8 and 24 week control groups had mean plasma HbAlC levels of 3.7 and 3.3 % 
respectively, whereas the hyperglycemic groups at 8 and 24 weeks had mean HbAlC 
levels of 8.0 and 7.1% respectively (Table 3). HbAlC levels reflect the degree of 
glycation on hemoglobin and subsequently blood glucose levels over the past 3-4 months. 
Because of this, we were able to get an accurate assessment of the glycemic state of the 
hamsters for the duration of the study, not just at the time they were sacrificed. This is 
important due to the extent of stress during sacrifice. Anesthesia principally affects 
glucose metabolism through the modulation of sympathetic tone; however, in vitro 
evidence exists that insulin secretion is suppressed by inhalational agents. The insulin 
deficiency as a result o f the anesthesia compounds the absolute insulin deficiency present 
in persons with diabetes, raising the risks of hyperglycemia and ketogenesis [105]. This
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effect could result in abnormally high glucose levels in both treatment and non-treatment 
hamsters during processing. The statistically significant differences in HbAlC levels 
accurately confirmed that STZ treatment resulted in elevated plasma glucose levels in the 
treatment groups during the duration of the study. Blood glucose values were far less 
consistent than the HbAlC values and are only able to depict a “snapshot” of the blood 
glucose concentration at the time the blood is drawn.
In order to determine whether the hyperglycemia and abnormal lipid profiles 
correlated to expression of the inflammatory transcription factor PPARy, 
immunohistocemical, ELISA, and western blot analyses were run to determine its general 
expression as well as expression of its active form. Various studies have indicated the 
importance of PPARy and its function in metabolic homeostasis and inflammatory 
control, including three studies that independently reported loss-of-function mutations in 
the ligand binding domain of human PPARy [106-108]. These individuals harbor 
dominant-negative mutant PPARy alleles that impair PPARy function by greater than 
50%. A summary of clinical features amongst these individuals include: early 
atherosclerosis, dyslipidemia, early hypertension, limb/gluteal lipodystrophy, severe 
insulin resistance, polycystic ovaries and hepatic steatosis. Most of these subjects had 
marked and sometimes extreme dyslipidemia that was characterized by high TG and low 
HDL-C levels, a phenomenon that we observed in our hamsters specifically in the treated 
groups. This raises the question of whether individuals with hyperglycemia also have 
modified expression of PPARy. As stated earlier, a crucial indication of the importance of 
PPARy was highlighted when it was discovered as the cognate receptor for the insulin 
sensitizing TZDs [109]. We questioned whether the effects of PPARy activation were
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important outside of its clinical role as a receptor for TZD ligand activation. Are 
endogenous levels of PPARy affected by glycemic status? Unfortunately, no differences 
were observed when we ran an ELSIA of representative samples to assess active PPARy 
expression although presence of active PPARy was noted in each group. Although the 
results from the immunohistochemical analysis are technically not quantitative, it was 
observed that the reaction became more intense with increasing development of the 
lesions. Because PPARy is expressed in adipose tissue, and developing lesions are 
characterized by influx of lipid, this could possibly explain the increase in 
immunoreactivity in the developing lesions; the extremely elevated TG levels could also 
provide substrate for PPARy activation. In addition to being present in adipose tissue, 
PPARy is also present in skeletal muscle, as well as within atherosclerotic lesions[45]. 
Thus, the effects of PPARy activation on atherosclerosis are both indirect, improving 
insulin sensitivity, and direct, affecting gene expression in the vessel wall, or more 
specifically within atheromic macrophages. PPARy activation regulates both pro- and 
antiatherogenic genes involved in cholesterol homeostasis. PPARy was found to 
stimulate transcription of the CD36 gene which is a macrophage scavenger receptor that 
traditionally contributes to foatm cell formation and development of atherosclerosis in 
mice [110]. In concert with the finding that PPARy can be activated by the fatty acid 
metabolites 9- and 13-hydroxyoctadecadenoic acids (9- and 13-HODE) present in 
oxLDL-C, a PPARy cycle has been proposed in which oxidized lipids would induce 
activity of PPARy, leading to the increased expression of CD36, which in turn would 
increase oxLDL-C uptake. This process would prove detrimental in the progression of 
atherosclerosis by promoting foam cell formation. PPARy has also been shown to induce
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expression of LXRa, thereby stimulating expression o f ABCAl-depednent cholesterol 
efflux. Hypothetically, an even more complex cycle might exist in which there is a 
concomitant increase in CD36 and ABCA1 resulting in clearance of the detrimental lipid 
within the atheroma to resident macrophages for removal by ABCA1 back to the liver. If 
these genes were co-stimulated in the manner described, upregulation of PPARy would 
prove beneficial in slowing and possibly reversing lesion progression. In order to test this 
hypothesis, this study analyzed expression of endogenous lesional ABCA1 expression 
through immunohistochemical analyses. Although we did not obtain any quantitative 
results, similar to the immunoreactivity for PPARy, ABCA1 reactivity became more 
intense with increasing development of the fatty streak lesions. Immunoreactivity tended 
to increase over time (8 to 24 weeks) and with initiation of treatment (STZ). ABCA1 
expression and activity at the macrophage and hepatic levels is critical regarding lipid 
efflux and HDL-C formation which in turn could influence the progression of 
atherosclerotic plaques. Interestingly, the lowest levels of HDL-C were found in the 24 
week treated hamsters, but the most complex lesions were also observed within this 
group. This begs the question of whether there really is an increased concentration of 
ABCA1 with increasing complexity of the lesion, and if so, why are HDL-C levels still 
declining? One possible explanation is the extreme nature with which the lipid profiles 
were altered. Although activated PPARy was detected by ELISA in all groups, there were 
no statistical differences between them. However, average 8 week treated values were 
higher than 8 week controls and 24 week controls were higher than both 8 week control 
and treated aortas. PPARy may have the ability to act like a “lipid sensor”, gauging 
changes in endogenous cholesterol homeostasis. In the hyperglycemic state, lipid profiles
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are altered, and concentrations of circulating FFAs are increased. This increase in FFAs, 
which are endogenous ligands of PPARy, could stimulate activation of PPARy, causing a 
downstream upregulation of ABCA1. This mechanism would be activated in times of 
dyslipidemia as an attempt to positively influence lipid profiles (stimulate HDL 
formation). But, upregulating ABCA1 could lack a downstream effect due to the extreme 
alterations observed in the treated animal’s lipid levels. Overall, the PPAR-LXR-ABCA1 
cascade has a significant role in cholesterol homeostasis and inflammation and there is 
promising potential for therapeutic manipulation outside of the insulin sensitizing effects 
of TZDs. Further work needs to be carried out in which other functions of PPARy and the 
cholesterol transporter ABCA1 as well as their pathways are elucidated so that strategies 
can be developed to prevent atherosclerotic disease and its extensive complications.
Summary:
We found that hyperglycemia and associated altered lipid profiles amplifies the 
negative effects of a hyperlipidemic diet through increased total cholesterol levels, non 
HDL-C levels, triglycerides and decreased HDL-C levels. In the present study, hamsters 
fed the high fat/high cholesterol diet developed early fatty streak lesions consisting of 1 
to 2 layers of foam cells. How ever, the hamsters that were also treated with STZ 
developed hyperglycemia and larger, more developed lesions. Lesions characteristic of 
the 24 week treatment hamsters invaded the luminal space of the aorta due to increased 
lipid accumulation within larger foam cells. One observed possibility for the increase in 
atherosclerosis in the treated hamsters was the significantly decreased levels of serum 
HDL-C, the lipoprotein responsible for RCT. Decreased levels of HDL-C might slow the
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process of lipid removal from peripheral tissue (e.g. arterial lesions) for processing in the 
liver. In order to analyze other mediators of the reverse cholesterol transport pathway, 
this study observed expression of ABCA1. The expression of ABCA1, based on IHC 
immunoreactivity, seemed to increase with developing complexity of the lesion and with 
time. Overall, based on IHC immunoreactivity, the 8 week treatment and control sections 
exhibited staining that was moderately dispersed throughout the endothelial cells and 
tunica media. As treatment time increased and subsequently lesion size, ABCA1 
expression tended to intensify and localize to lipid laded foam cells. This possible 
increase could represent a feedback mechanism in response to the elevated concentrations 
of lipid. This study also analyzed expression of the inflammatory, nuclear transcription 
factor, PPARy which has been shown to regulate ABCA1 as wells as other pro- and 
antiatherogenic genes [45], Based on our investigation, active PPARy expression did not 
change with fluctuations in glycemic status (without TZD treatment), as we did not find a 
difference in expression in our treatment hamsters as compared to the euglycemic 
controls. Overall, it appears that hyperglycemia is amplifying the dyslipidemic affects of 
a high fat/high cholesterol diet; possibly providing one reason for the associated 
increased risk of CVD in diabetic individuals. Further work needs to be undertaken to 
uncover the effects of altered lipid metabolism and RCT in the progression of 
atherosclerosis.
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